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Prologue 
The history of gastric acid related disease and treatment 
The chemistry of gastric acid was described at the beginning 19th century, when 
William Prout showed that the stomach of animals contains “muriatic acid”.2 Muriatic acid is a 
historical term for hydrochloric acid (HCl) that is contained in the gastric juice.3 In the first 
decade of the 20th century, gastric acid was observed to play a key role in erosive processes 
of peptic ulcer diseases.4-6 At that time it was also noticed that characteristically peptic ulcer 
diseases develops from mucosal lesions of the esophagus, the stomach and upper parts of 
the small intestine.7 Mucosal exposure to gastric acid and pepsin may lead to erosive 
ulceration penetrating bottom tissue layers.7 
Peptic ulcer diseases frequently cause patients to suffer from “dyspepsia” with 
symptoms such as fullness, bloating, satiety or nausea and especially during fasting periods 
also from severe heartburn.8 Complicating factors are bleeding, eventual perforation of 
ulcerated gastrointestinal epithelium and stenosis.9, 10 Until the last decades of the 20th 
century gastric acid related disorders were a severe pathological threat..11 Difficult to treat, 
they significantly contributed to population morbidity and mortality.11-13 Treatment options 
were restricted to chemical antacids (acid binders) having minor efficacy. Alternatively, there 
were surgical methods such as partial gastrectomy to remove gastric acid producing tissues 
or vagotomy to cut neural activation of acid production.14 
The management of gastric acid related diseases such as peptic ulcer diseases and 
gastroesophageal reflux disease had a breakthrough in the late 1970s. GlaxoSmithKline 
launched the first anti-secretory drug cimetidine to the market. It was the first drug in a 
pipeline of several other histamine-2 receptor antagonists blocking histamine triggered acid 
secretion.15-18
The development of PPIs  
While H2RAs became quickly established in clinical practice, Astra-Zeneca was 
already developing a completely different anti-secretory weapon.19, 20 Following the classical 
lead-compound approach, systematically direct blockers of the gastric proton-pump (the 
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gastric H+,K+-ATPase) were explored.21 The initial drug molecule timoprazole lacked specificity 
and caused inhibition of iodine uptake in the thyroid gland, which prevented further clinical 
trials.21-24 The related molecule picoprazole passed pharmacological safety tests and went into 
pharmacological studies in humans.20 Subsequent refinement of its chemical structure 
resulted in omeprazole (tradename Losec), the first proton-pump inhibitor (PPI) that became 
available at the European market in 1988.21, 25, 26 Omeprazole has a superior pharmacological 
profile, which led to widespread use.27-29
The current status of PPIs 
Still, omeprazole is the most widely used PPI in clinical practice. Over the years, four 
chemically closely related derivates have been released (named esomeprazole, lansoprazole, 
pantoprazole and rabeprazole).30, 31 All PPIs are primarily indicated for the treatment of gastric 
acid-related disorders32, 33 PPIs belong to one of the bestselling drug classes of the last decade 
and are chronically used by millions of patients worldwide with continuously growing 
prescription.34 Between 2009 and 2014 the total amount of PPI doses prescribed on annual 
basis in The Netherlands raised from 4.5 to 6.6 million with total costs of 110 million Euros in 
2014. In that year PPIs were prescribed to 2 million patients, that is 13% of the entire Dutch 
population.35 
Several factors contributed to this development. From a clinical perspective, PPIs are 
the first choice for treatment of gastric acid related diseases.36 The change in our lifestyle 
contributes to the growing success of PPIs. High caloric intake, low physical activity and 
resulting overweight predisposes to develop reflux.37 This explains why 40% of all individuals 
are confronted with gastroesophageal reflux disease at least once in their lifetime.38, 39 
Moreover, PPIs are frequently prescribed without proper indication or are not terminated 
upon disappearance of the indication.40-42 Recent studies demonstrate inappropriate 
prescription in 50-80% of patients.43 Adherence to PPIs is strong in chronic users as PPI use 
itself is capable of generating dyspeptic symptoms upon withdrawal.44 Given that widely used 
PPI’s omeprazole and pantoprazole are allowed for over-the-counter sale makes PPIs freely 
available and predisposes for later prescription.45 
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The (patho-)physiology of gastric acid 
Gastric acid related diseases 
 
In fasting conditions intragastric pH drops to pH 1-3 and is normally maintained 
below pH 4.46, 47 The luminal surface of the gastric lining is coated with bicarbonate rich mucus 
in order to protect the epithelium from acidic burn and from auto-digestion by pepsin.48-51 
However, exposure of epithelium that is unprotected by mucus leads to serious lesions.52 
Peptic ulcer disease is the primary indication for PPIs and can have multiple origins. First, 
chronic use of NSAIDs has been linked to peptic ulcers.53 NSAID-induced lesions are caused 
by reduced prostaglandin production, which is needed to maintain mucus production.51 
Second, hypersecretion resulting from enhanced sensitivity to gastrin or enhanced gastrin 
levels may require PPI intake.54, 55 Third, Zollinger-Ellison syndrome is caused by endocrine 
pancreatic islet tumors (sometimes also located in stomach and duodenum) that uncontrolled 
secrete gastrin.56-58 Fourth, conditions of chronic reflux leads to mucosal lesions, since the 
epithelium of the esophagus has low resistance to gastric acid. Chronic reflux predisposes to 
develop esophageal cancers although the risk in individuals seems to be low.59, 60  
 
The basis of gastric acid secretion 
 The native molecular target of PPIs is the parietal cell that lines the mucosa of the 
stomach and secretes gastric acid.61 The daily production of gastric juice equals 2 liters.62, 63  
Gastric acid secretion depends on the fusion of H+,K+-ATPase-rich vesicles with the 
apical membrane, which initiates pumping of the protons needed to form the gastric 
acid (Figure 1).64, 65 Upon combined signaling via basolateral receptors, acetylcholine, 
gastrin and histamine increase total secretory activity of the parietal cell.66 Histamine 
is the central mediator and the strongest activator of proton secretion.67-69 This is 
supported by the fact that H2RA are able to reduce acid secretion, even in conditions 
of increased levels of gastrin and acetylcholine.70 
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Figure 1. Schematic the parietal cell in resting (A) and activated state (B). Upon cumulative activation of 
basolateral receptors for gastrin (CCK3), acetylcholine (Muscaric/M3) and histamine (H2) sequestered 
H+,K+-ATPase-rich vesicles fuse with the apical membrane, leading to enlargement of the canalicular 
labyrinth and extrusion of protons. Concomitant efflux of choride (Cl-) leads to formation gastric acid 
(HCl). 
PPI´s mode of action and specificity 
The therapeutic effect of PPIs is based on direct inhibition of the gastric H+,K+-ATPase 
pore. The gastric H+,K+-ATPase is a member of IIc subgroup of P-type ATPase superfamily and 
its structure is closely related to that of the non-gastric H+,K+-ATPase and the Na+,K+-
ATPase.71, 72 The gastric proton pump is a heterodimeric enzyme complex of 147 kDa, encoded 
by two genes.73 Firstly, the large alpha-subunit (ATP4A) that harbors the transporting and the 
catalytic function.74 Secondly, the beta-subunit (ATP4B).75 The beta-subunit has regulatory and 
structural functions and determines ion selectivity of the complex. Moreover, ATPase activity 
is directly dependent on co-expression of the beta-subunit. However, the exact interactions 
between the alpha- and beta-subunits is not well understood as there are functional 
differences between different species.76, 77 
A B 
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Oral PPI-therapeutics are taken up by the small intestine and are distributed by the 
circulation throughout the body.78 PPIs are lipophilic prodrugs and reaching the parietal cell, 
they rapidly accumulate in the acidic microenvironment of the canalicular labyrinth.79, 80 Here, 
the PPI-prodrug is protonated and converted into the active metabolites that bind to the 
gastric H+,K+-ATPase.26, 81 The specificity of PPIs for binding to the gastric H+,K+-ATPase is 
mainly based on two aspects: the acidity of the reaction compartment and the presence of 
binding motifs on the ATPase itself.78  
 
Proton pump inhibitor-induced hypomagnesemia  
 
It is widely assumed that PPIs have an excellent safety profile.82 They are the most 
potent blockers of gastric acid production, which explains their efficacy in the treatment of 
the indicated diseases.83 Nevertheless, lagging the introduction of PPIs with almost a decade, 
Epstein et al. reported two cases having hypomagnesemia due to PPIs in 2006.84 Normal serum 
Mg2+ ranges between 0.7-1.1 mmol/L (1.5-2 mEq/L; 1.7-2.4 mg/dL).85 The term 
hypomagnesemia describes a state of Mg2+ deficiency that is reflected by a serum Mg2+ 
concentration of <0.7 mmol/L. Since 2006, hypomagnesemia became the most recognized 
side effect of PPIs, termed PPI-induced hypomagnesemia (PPIH). After the initial publication, 
approximately 100 cases of PPIH have accumulated until today.86-100 The U.S. Food and Drug 
Administration issued a warning on this side effect in 2011.101 Subsequently, clinical studies 
have been initiated, mostly of retrospective character, aiming to estimate clinical impact and 
risk factors for PPIH.102-104 
From the low number of cases, in comparison with the millions of patients using PPIs 
it is anticipated that PPIH has a low incidence, possibly affecting 1% of all PPI-users.105 
However, at the same time, analysis of the FDA drug adverse event data indicates that many 
cases exist and PPIH may therefore be more frequently present in clinical practice than 
formerly thought.106 For instance, a recent screen of the Dutch pharmacovigilance databank 
Lareb lists a total number of 58 symptomatic cases being reported between 2008-2015 (Figure 
2A). With 8-10 new cases on yearly basis between 2009 to 2012 and with a peak of 15 new 
cases in 2013 (Figure 2B). 
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All listed cases of PPIH came to clinical attention by hypomagnesemia-associated 
symptoms such as tetany, seizures, paresthesia, ataxia, fatigue, confusion, other 
neuromuscular signs and cardiac arrhythmia.88, 89, 107 Due to the lack of clinical awareness, it 
may take years to diagnose PPIH putting these patients at risk.94, 95 Given that asymptomatic 
cases are only found incidentally, as serum Mg2+ is not checked routinely in PPI users, 
presumes an unknown number of undetected cases.89, 108 
Figure 2. Dutch cases of PPIH listed in pharmacovigilance database Lareb between 2008 and 2015. Panel 
A represents the accumulated number of cases, panel B the number of new cases reported per year. 
Apart from hypomagnesemia, secondary hypocalcemia and hypokalemia is 
frequently present in cases of PPIH, sometimes with concomitant hypoparathyroidism.84, 98 
The only reliable method to diagnose PPIH is drug (de-)challenge, which leads to 
normalization of serum Mg2+ upon withdrawal, and to refractory hypomagnesemia upon 
reintroduction of any PPI.94, 95 This suggests that PPIH is a drug-class effect, with obscure dose-
dependency.109  
Based on lacking knowledge of the molecular mechanism of PPIH, its treatment was 
mainly driven by trial and error and did not result in reliable treatment methodologies. 
Available Mg2+ supplementation strategies were prone to fail compensating the 
hypomagnesemia on the long term.109, 110 And lacking any equally efficient anti-secretory 
drugs, a dilemma arises for PPIH patients with strong indication for PPIs. Inevitable PPI 
continuation keeps disturbing Mg2+ homeostasis and maintains Mg2+ depletion and 
symptoms. 
A B 
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Table 1. Distribution and Mg2+concentration in the human body,  
 percentage   concentration 
Tissues:    
bone 65 %  0.5% of bone ashes 
muscle 27 %  3.5-5 mmol/kg  
other 6-7 %  3.5-5 mmol/kg  
extracelluar + erythrocytes < 1 %   1.65-2.73 mmol/L 
Serum:   0.65-0.88 mmol/L 
free, ionized 55 %  0.48-0.66 mmol/L 
bound to albumin 32 %   0.1-0.3 mmol/L 
            (Adapted from)1 
Magnesium homeostasis 
Distribution of Mg2+ in the human body 
A human body of 70 kg contains on average 20-28 gr of Mg2+.1, 111 Mg2+ is the most 
prevalent divalent cation inside the mammalian cell with concentrations ranging between 
0.25-1 mmol/L and peaking up to 2.7 mmol/L in erythrocytes.112, 113 Sixty-five percent of all 
Mg2+ is located in apatite, the construction material of bone (Table 1). Another 33% is located 
in muscle, other tissues and organs such as brain, parathyroid gland, liver and kidney. The 
remaining 1% of Mg2+ is present in extracellular compartments and the blood plasma. Given 
that plasma Mg2+ levels only reflect 0.3% of the total Mg2+ body content, the serum Mg2+ level 
is a weak indicator of the overall body Mg2+ status. Only 55-70% of the total plasma Mg2+ is 
present in the ionized form, ready to be used in biological processes, whereas the remaining 
30-45% is bound to proteins or anions.114  To fulfill its role as transport medium, plasma Mg2+ 
levels are the kept in a narrow range by a concerted interplay  intestinal Mg2+ uptake, renal 
filtering of Mg2+ and its storage in bones and soft tissues.115, 116  It has been shown that PPI 
use is inflicted in intestinal malabsorption of Ca2+ leading to disturbances of bone mineral 
deficits.117 This assumption promoted the idea that intestinal failure of Mg2+ absorption would 
be the basis for PPIH. 
 
 
 
 
 
 
Dietary intake of Mg2+  
 Primary sources for body Mg2+ are green leafy vegetables rich in fibers and 
chlorophyll (e.g. legumes, spinach) and seeds, whole grains and nuts.118 Tap water and bottled 
mineral waters are good sources of Mg2+ (up to 30 mg/L Mg2+) as well.119-121 The 
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recommended daily intake for humans (RDA) for Mg2+ ranges between 300 to 350 mg per 
day and depends on age, sex and pregnancy Table 2).122,123 An average single meal contains 
90 mg Mg2+ and the daily intake ranges between of 250 to 350 mg Mg2+.124 This means that 
many individuals do not ingest the RDA of Mg2+.123 It has been observed that 70-80% of 
different American populations do not reach appropriate RDA, suggesting widespread Mg2+ 
underprovision possibly having an impact on health.125-128  
The composition of the diet composition plays a crucial role in intestinal Mg2+ 
availability. Only ionized Mg2+ can pass the mucosa of the intestine and enter into the 
bloodstream.129 Naturally occurring chelators such as phytic acids, insoluble fibers and 
oxalates reduce Mg2+ absorption.130-133  
Intestinal Mg2+ absorption  
Bodily requirements and nutritional status determine that 24-76% of the dietary 
Mg2+ content is absorbed by the intestine(Figure 3A).134 Two mechanisms constitute intestinal 
Mg2+ absorption: passive paracellular diffusion, driven by the electrochemical gradient and 
active transcellular transport, mediated by specific Mg2+ transporters.115 In the small intestine, 
Mg2+ absorption mainly occurs by paracellular transport accounting for uptake of 30% of 
dietary Mg2+.120 Paracellular transport is dependent on the conductivity of the tight junctions. 
Members of the claudin family, integral membrane proteins, residing in the tight junctions are 
suspected to regulate Mg2+ absorption.135, 136, 137 In the distal segment of the small intestine 
Table 2. Recommended dietary allowances (RDA) for Mg2+ in mg/day 
age male female pregnancyy  lactation 
0-6 months 30 30 
7-12 months 75 75 
1-3 years 80 80 
4-8 years 130 130 
9-13 years 240 240 
13-18 years 410 360 400 360 
19-30 years 400 310 350 310 
31-50 years 420 320 360 320 
51+ years 420 320 
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and in the large bowel Mg2+ is absorbed transcellularly, facilitated by the Transient Receptor 
Potential channel Melastatin member 6 (TRPM6) divalent cation channel.138 139, 140  TRPM6 
forms the selective apical entry pathway for Mg2+ in the enterocytes.141 Its functional 
importance in maintaining intestinal Mg2+ absorption (and renal Mg2+ reabsorption) has been 
demonstrated in patients with genetic defects leading to hypomagnesemia and secondary 
hypocalcemia (HSH).142 Approximately 5% of dietary Mg2+ is reabsorbed in the colon fine-
tuning intestinal Mg2+ uptake. 115, 143 The remaining 65% of dietary Mg2+ intake leaves the 
body with the feces.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Mg2+ uptake in the intestine. Panel A depicts contribution of the different intestinal segments 
to Mg2+ absorption. Segments are grouped by predominant transcellular versus paracellular mechanisms 
being present. Panel B sketches transcellular versus paracellular Mg2+ absorption. Transcellular TRPM6-
mediated Mg2+ absorption takes place in the large intestine. Here the paracellular route is blocked by 
tight claudin complexes. The release of protons by the H+,K+-ATPase apical microenvironment enhances 
TRPM6 channel function. Mg2+ enters the cell and is extruded to the blood side by an unidentified 
mechanism. The small intestine is characterized by paracellular Mg2+ fluxes, facilitated by differential 
expression of claudin proteins residing in the tight-junctional complexes, with minor contribution of 
TRPM6. How and which members of claudin family regulate intestinal Mg2+ absorption is understood. 
 
A B 
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Mg2+ is stored in bone material together with Ca2+.144, 145 The Mg2+ embedded in 
bone structure therefore does not readily contribute to serum Mg2+ stabilization. Retrieval of 
Mg2+ from its storage is therefore dependent on trabecular remodeling by parathyroid 
hormone.146 The Ca2+ sensing receptor steers secretion of parathyroid hormone and is 
differentially responsive to extracellular Mg2+ depending on actual serum Ca2+ levels.147 
Therefore, primarily intestinal Mg2+ uptake acquires the Mg2+ essential to maintain 
serum Mg2+ levels.148 The kidney is the organ that restricts Mg2+ excretion at low Mg2+ intake 
by upregulation of the TRPM6 channel.141, 149 
Regulation of TRPM6 and the phenomenon of insulin resistance 
TRPM6-mediated Mg2+ fluxes are tightly regulated by many biochemical and 
endocrine factors, including intracellular Mg2+ and ATP.141,150,151 TRPM6 is sensitive to 
extracellular pH as the channel carries luminal residues that can be protonated and which 
increases TRPM6 currents (Figure 3B).152, 153 TRPM6-mediated Mg2+ absorption may therefore 
be modulated by extracellular pH of the primary urine or of the intestinal lumen. 
Currently, two hormones have magnesiotropic properties. The epidermal growth 
factor EGF regulates abundance of TRPM6 at the cell membrane.154 Estrogen stimulates 
TRPM6 activity in short term and on long term it enhances TRPM6 mRNA expression.150 Likely, 
this explains alleviation of hypermagnesuria in women by receiving estrogen substitution 
during their menopause.149, 155, 156 Disturbances of Mg2+ homeostasis are associated with 
insulin resistance, diabetes mellitus type 2 and metabolic syndrome.157, 158 Mg2+ intake 
inversely relates to the risk of diabetes mellitus.159 Carriers of the two non-synonymous SNPs 
in TRPM6 (Val1393Ile in exon 26 [rs3750425] and Lys1584Glu in exon 27 [rs2274924]) have a 
significantly higher risk for diabetes mellitus when their magnesium intake is lower than 250 
mg per day.160 TRPM6 channels carrying these SNPs feature loss of insulin-induced 
activation.161 
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State-of-the-art 
Current understanding of PPIH 
 It is hypothesized that PPIH is caused by intestinal malabsorption, because oral Mg2+ 
supplementation has minor effect and because cases document adequate renal retention 
upon Mg2+ loading.86 This assumption has recently been substantiated as PPI use is associated 
with lower renal Mg2+ excretion likely secondary to reductions of intestinal Mg2+ 
absorption.162 The intestinal phenotype sets PPIH apart from all other known types of drug-
induced hypomagnesemia where renal wasting is the culprit.163 Paralleling the poorly based 
explanatory attempts for deficient intestinal Ca2+ absorption by PPIs, it was believed that PPIH 
derives from generalized hypochlorhydria, without determination of the exact molecular 
mechanism (reviewed in 117).164 Scarce in vitro data suggests that PPIs would interfere with 
paracellular (claudin-mediated) Mg2+ fluxes which can be compensated by acidification.165, 166 
These findings lack translatability to clinical PPIH in humans, because high oral Mg2+ 
supplementation was effective in a few cases which indicates the paracellular pathway to be 
intact.93 Consequently, transcellular TRPM6-mediated Mg2+ absorption was an early suspect.93 
Despite of the assumption that a genetic cause for PPIH might exist, probably located in 
TRPM6 or its regulation, it was not investigated systematically.93, 167  
 
The Patient at Risk 
The risk profile for PPIH is poorly understood.104 With varying success rate, known 
general confounders for hypomagnesemia were utilized as possible predictors of PPIH, such 
as use of diuretics.103, 168 Characteristically, PPIH affects differentially (severely) comorbid 
patients of age above 50 years, after years of chronic PPI use. However, there are a few reports 
of acute onset of PPIH in patients with preexisting Mg2+ depletion due to other reasons. 205, 
206 World-widely appearing cases suggest that PPIH is not restricted by ethnicity.84, 86, 90, 104, 107, 
109, 110, 169 Currently, no proof substantiates that the slow hepatic PPI-metabolizing genotype 
would be a prerequisite for PPIH.88 Genetic variants in the Mg2+ channel transient receptor 
potential melastatin 6 (TRPM6) have been suggested, but a screen was negative.93, 167  
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Current treatment of PPIH 
Treatment of PPI-related hypomagnesemia is based on parenteral electrolyte and/or 
oral supplementation.85, 170 Parenteral supplementation is indicated for acute symptom relief 
and requires hospitalization, whereas oral supplementation aims to replenish body Mg2+ 
levels on long term. Restricted tolerability of oral Mg2+ supplements is problematic as high 
doses induce osmotic diarrhea, potentially rendering comedication inefficient and leading to 
intestinal Mg2+ losses.171 Due to the defect of intestinal Mg2+ absorption, frequently oral Mg2+ 
supplementation fails, causing recurrent hypomagnesemia. The gold standard to treat PPIH is 
drug withdrawal. It leads to brisk normalization of serum Mg2+ but consequently imposes 
tradeoffs in gastric acid protection. H2RAs were utilized to compensate gastric acid at PPI 
withdrawal but it works only in some patients and others are left either with dyspeptic 
symptoms or recurrent hypomagnesemia under continuation of PPIs.94,95, 110, 172 Initial 
attempts have been made to introduce patients to a H2RA/PPI intermitting protocols, but 
these may apply only to a resticted group of acid tolerable patients.169 Both situations bring 
health risks for the affected patients and renders the effective circumvention of PPIH 
problematic as alternative treatment methodologies are unavailable. 
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Outline of this thesis 
The aims of this thesis are (i) to gain better understanding of the physiological 
molecular mechanism(s) involved in PPIH; (ii) to develop the knowledge on the factors 
contributing to better and earlier identification of the patient at risk for PPIH; (iii) to provide 
clinical tools to overcome PPIH; (iv) to contribute to the general knowledge of Mg2+ 
homeostasis in health and disease.  
 
The research presented here is guided by the following central research objectives: 
1. What is the molecular mechanism of PPIH and which are the molecular 
players being involved?  
2. What is the current prevalence of PPIH?  
3. Which are the determinants in patients predisposing for PPIH?  
4. Does a TRPM6-mediated disposition contribute to PPIH?  
5. Are there alternative strategies that can be utilized to improve the 
treatment for PPIH?  
 
Thesis overview 
Chapter 2 provides a comprehensive pharmacological animal experiment in which 
mice have been challenged with the PPI omeprazole and Mg2+-deficient diets, in order 
examine validity of our model for PPIH and to identify molecular players involved in PPIH 
(objective 1). Therefore, we determined serum und urinary Mg2+ levels and investigated mRNA 
expression patterns of magnesiotropic genes and the H+,K+-ATPases in the large intestine and 
the kidney. Chapter 3 examines a possible new treatment option for PPIH in mice by means 
of dietary inulin fibers (objectives 1 & 5). Therefore, we treated mice with omeprazole and 
supplemented them with dietary inulin. In coherence to Chapter 2, serum Mg2+ levels and 
urinary Mg2+ excretion was assessed, as well as mRNA levels of TRPM6 and the non-gastric 
H+,K+-ATPase. In parallel, the effects of omeprazole treatment and inulin supplementation on 
Ca2+ homeostasis were scrutinized.  
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Preceding any further clinical investigation, in Chapter 4 we investigated reported 
cases of PPIH by a meta-analytical approach that condenses fragmentary clinical knowledge 
(objectives 3, 4 & 6). The systematic review particularly examines common risk factors, 
evaluates the kinetics of serum Mg2+ in PPIH and summarizes current treatment options and 
their outcomes. 
Chapter 5 describes a comprehensive clinical study that holistically approaches all 
aspects of PPIH (objectives 2, 3, 4, 5 & 6). The study prospectively detected the clinical 
prevalence of PPIH, it extracted common risk factors and investigated whether TRPM6 harbors 
a genetic predisposition for PPIH. Finally, the various studies are discussed and summarized 
in Chapter 6 that integrates gained knowledge of this thesis in order to explain, to predict 
and to treat PPIH. 
Introduction to PPIH 
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Abstract 
Proton pump inhibitors (PPIs) are potent blockers of gastric acid secretion, used by 
millions of patients suffering from gastric acid-related complaints. Although PPIs have an 
excellent safety profile, an increasing number of case reports describe patients with severe 
hypomagnesemia due to long-term PPI use. As there is no evidence of a renal Mg2+ leak, PPI-
induced hypomagnesemia is hypothesized to result from intestinal malabsorption of Mg2+. 
The aim of this study was to investigate the effect of PPIs on Mg2+ homeostasis in an in vivo 
mouse model. To this end, C57BL/6J mice were treated with omeprazole, under normal and 
low dietary Mg2+ availability.  
Omeprazole did not induce changes in serum Mg2+ levels (1.48 ± 0.05 mmol/L and 
1.54 ± 0.05 mmol/L in omeprazole-treated and control mice, respectively), urinary Mg2+ 
excretion (35 ± 3 µmol/24 h and 30 ± 4 µmol/24 h in omeprazole-treated and control mice, 
respectively) or fecal Mg2+ excretion (84 ± 4 µmol/24 h and 76 ± 4 µmol/24 h in omeprazole-
treated and control mice, respectively) under any of the tested experimental conditions. 
However, omeprazole treatment did increase the mRNA expression level of the transient 
receptor potential melastatin 6 (TRPM6), the predominant intestinal Mg2+ channel, in the colon 
(167 ± 15% and 100 ± 7% in omeprazole-treated and control mice, respectively, P < 0.05). In 
addition, the expression of the colonic H+,K+-ATPase (cHK-α), a homolog of the gastric H+,K+-
ATPase that is the primary target of omeprazole, was also significantly increased (354 ± 43% 
and 100 ± 24% in omeprazole-treated and control mice, respectively, P < 0.05). The expression 
levels of other magnesiotropic genes remained unchanged.  
Based on these findings, we hypothesize that omeprazole inhibits cHK-α activity, 
resulting in reduced extrusion of protons into the large intestine. Since TRPM6-mediated Mg2+ 
absorption is stimulated by extracellular protons, this would diminish the rate of intestinal 
Mg2+ absorption. The increase of TRPM6 expression in colon may compensate for the reduced 
TRPM6 currents, thereby normalizing intestinal Mg2+ absorption during omeprazole treatment 
in C57BL/6J mice, explaining unchanged serum, urine, and fecal Mg2+ levels. 
Keywords: Hypomagnesemia; Mg2+; Omeprazole; ATP12a; H+,K+-ATPase; TRPM6 
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Introduction 
 Proton pump inhibitors (PPIs) are indicated for gastric acid-related diseases like 
gastroesophageal reflux disease, Zollinger-Ellison syndrome, Barrett’s esophagus, duodenal 
peptic ulcers, and gastritis.1 All PPIs have a similar chemical structure and an identical mode 
of action. They are administered in the form of lipophilic, membrane-permeable, inactive pro-
drugs.2 PPIs are absorbed from the small intestine into the blood, after which they accumulate 
in the highly acidic canaliculi of the parietal cells of the stomach. Here, PPIs are protonated, 
which induces covalent binding between the PPI and specific cysteine residues of the gastric 
H+,K+-ATPase (gHK-α), resulting in potent inhibition of acid secretion.2 Although PPIs are 
generally considered to have an excellent safety profile, over 65 cases of PPI-induced 
hypomagnesemia (PPIH) have been reported since 2006.3-15 In addition to these case reports, 
reduced serum Mg2+ levels associated with the use of PPI’s were reported in a cohort of 
hospitalized patients.16 A recently published study, based on reports submitted to the Adverse 
Event Reporting System of the US Food and Drug Administration, suggests that PPIH might 
concern several hundreds of patients since 2004.17 
 PPIH typically manifests after years of chronic PPI use, and patients present with 
symptoms common to severe Mg2+ depletion such as tetany, seizures, convulsions, and 
cardiac arrhythmia, often coinciding with secondary hypocalcemia. The causal link between 
the use of PPIs and the development of hypomagnesemia was shown in PPIH patients by a 
classical challenge-dechallenge-rechallenge protocol, leading to fast recovery from 
hypomagnesemia during dechallenge and fast reappearance of hypomagnesemia after 
rechallenge.3, 7, 14 Intravenous Mg2+ loading tests indicate that PPIH patients are severely Mg2+ 
depleted, and determination of fractional Mg2+ excretion shows appropriate renal retention of 
Mg2+.3, 4, 12, 14 These findings implicate that intestinal malabsorption of Mg2+ plays a central 
role in the etiology of PPIH. This sets PPIH apart from many other forms of drug-induced 
hypomagnesemia which most frequently result from renal Mg2+ losses.18 However, the exact 
molecular mechanisms underlying PPIH remain unknown. 
 Some authors speculate that PPIH might result from genetic variants in the epithelial 
Mg2+ channel transient receptor potential melastatin 6 (TRPM6).3, 4, 12 The vital role of TRPM6 
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in the maintenance of Mg2+ homeostasis has been well established.19 The Mg2+ channel is 
expressed at the apical membrane of epithelial cells in the distal convoluted tubules of the 
kidney and at the luminal side of the gastrointestinal epithelium.20 Recently, several 
magnesiotropic hormones including epidermal growth factor, estrogen, and insulin have been 
described to influence Mg2+ absorption via TRPM6.21-23 In addition to the hormonal regulation, 
it is known that the presence of extracellular protons enhances inward currents via TRPM6, 
meaning that Mg2+ influx via this channel is strongly dependent on the extracellular pH.24 
 The primary target of omeprazole, gHK-α, has a homologue named the colonic 
H+,K+-ATPase (cHK-α), which extrudes protons into the lumen of the intestine in exchange for 
potassium ions.25 In vitro studies using guinea pig colonic crypts or colon tissue in Ussing 
chambers indicate that PPIs do not only reduce the activity of the gHK-α, but also that of the 
colonic H+,K+-ATPase (cHK-α).26, 27 Based on these observations, we hypothesize that 
omeprazole inhibits cHK-α activity, resulting in a lower amount of protons being extruded into 
the large intestine, subsequently leading to a reduced rate of intestinal Mg2+ absorption via 
TRPM6. 
 The aim of our study was, therefore, to create a mouse model of PPIH to test our 
hypothesis that omeprazole reduces TRPM6-mediated colonic Mg2+ absorption. To this end, 
we investigated the effect of omeprazole treatment on Mg2+ homeostasis in vivo by means of 
serum, urine, and fecal Mg2+ measurements and by determination of mRNA expression 
patterns of TRPM6 and cHK-α in the intestine and kidney. 
 
Materials and methods 
Animal studies 
 C57BL/6J mice (8 weeks old) were purchased from Charles River, the Netherlands. 
Animals were housed in a temperature- and light-controlled room with pelleted chow (SSNIFF 
Spezialdiäten GmbH, Germany) and drinking water available ad libitum. Omeprazole (Fagron, 
the Netherlands) was dispersed in a solution containing 0.5% (w/v) methylcellulose and 0.2% 
(w/v) NaHCO3 (pH 9.0). Mice received a daily dose of 20 mg omeprazole per kilogram 
bodyweight, which was administered via oral gavage. For urine and feces collection, animals 
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were individually housed in metabolic cages for 24 h. Blood was sampled from the 
submandibular facial vein at the end of the stay in the metabolic cages, and sera were collected 
for Mg2+ measurements. All experiments were performed in compliance with the animal ethics 
board of the Radboud University Nijmegen. 
 For the first experiment, animals were randomly divided into an omeprazole group 
(n=10) and a control group (n=10), receiving vehicle only. They were fed a standard chow with 
normal Mg2+ content (0.2% w/w Mg2+, SSNIFF Spezialdiäten GmbH, Germany) during 28 days. 
A second experiment was performed, in which both groups of mice were fed a Mg2+-deficient 
diet (0.02% w/w Mg2+, SSNIFF Spezialdiäten GmbH, Germany) for 22 days followed by a 
recovery period of 2 days in which the mice were reintroduced to a diet with normal Mg2+ 
content. 
 
Tissue collection and pH measurements 
 At the end of each experiment, blood was collected and animals were sacrificed via 
cervical dislocation under isoflurane anesthesia. Kidneys, duodenum, and colon segments 
were extracted, cleaned, and snap frozen in liquid nitrogen. In addition, stomach pH was 
analyzed using diagnostic test strips (Merck, Germany). 
 
Analytical procedures 
 Before analysis, fecal samples were homogenized and digested in 65% nitric acid 
(Sigma-Aldrich, USA) for 2 h at 70 C, followed by an overnight incubation at room 
temperature. Serum, urinary, and fecal Mg2+ concentrations were determined by a colorimetric 
xylidyl-II blue method (Cobas Roche Diagnostics, UK) on a Nanodrop 2000c 
spectrophotometer (Thermo Fisher Scientific, USA) at 600 nm wavelength and were verified 
using a commercial serum standard (Precinorm U, Roche, Switzerland). 
 
Quantitative real-time PCR 
 Total RNA was extracted from tissues using TRIzol reagent (Invitrogen, UK) 
according to the manufacturer’s protocol. The obtained RNA was subjected to DNase 
treatment (Promega, USA) to prevent genomic DNA contamination. Subsequently, RNA was 
reverse transcribed with murine leukemia virus reverse transcriptase. The obtained cDNA was 
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used to determine mRNA expression levels of various magnesiotropic genes and H+,K+-
ATPases, as well as mRNA levels of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as 
an endogenous control. The mRNA expression levels were quantified by real-time PCR on a 
CFX69 real-time detection system (BioRad, USA) using SYBR Green (BioRad, USA). Primers 
(Biolegio, the Netherlands) were designed with Primer 3 software (Whitehead Institute for 
Biomedical Research, USA) and are listed in Table 1. 
Table 1 Primer sequences used for real-time PCR. 
Statistics 
Values are expressed as means ± SEM. Differences between single groups of 
omeprazole-treated mice and controls were tested using a two-tailed, unpaired Student’s t 
test. Comparison of multiple groups was performed by a one-way ANOVA with a Bonferroni 
correction. Differences between groups were considered to be statistically significant when P 
< 0.05. Analysis of the datasets was performed using GraphPad Prism (Macintosh version, 
4.51). 
Gene NCBI ref. Forward primer Reverse primer 
GAPDH NM_008084.2 5’-TAACATCAAATGGGGTGAGG-3’ 5’-GGTTCACACCCATCACAAAC-3’ 
TRPM6 NM_153417.1 5’-AAAGCCATGCGAGTTATCAGC-3’ 5’-CTTCACAATGAAAACCTGCCC-3’ 
cHK-α NM_138652.2 5’-GCTAAGGCAACGCGCGTCCT-3’ 5’-CTGTTTTCCGGCGCATACTGTGA-3’
TRPM7 NM_021450.2 5’-GGTTCCTCCTGTGGTGCCTT -3’ 5’-CCCCATGTCGTCTCTGTCGT-3’ 
EGF NM_010113.3 5’-GAGTTGCCCTGACTCTACCG-3’ 5’-CCACCATTGAGGCAGTATCC-3’ 
EGFR NM_207655.2 5’-CAGAACTGGGCTTAGGGAAC-3’ 5’-GGACGATGTCCCTCCACTG-3’ 
Kv1.1 NM_010595.3 5’-CTGTGACAATTGGAGGCAAGATC-3’ 5’-GAGCAACTGAGCCTGCTCTTC-3’ 
CNNM2 NM_033569.3 5’-GGAGGATACGAACGACGTG-3’ 5’-TTGATGTTCTGCCCGTACAC-3’ 
HNF1B NM_009330.2 5’-CAAGATGTCAGGAGTGCGCTAC-3’ 5’-CTGGTCACCATGGCACTGTTAC-3’ 
gHK-α NM_018731.2 5’-TCCAGCAGGGATTCTTCAGGAAC-3’ 5’-AGCCAATGCAGACCTGGAACAC-3’
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Results 
Effect of omeprazole on serum Mg2+ levels as well as 24-h urinary and fecal Mg2+ excretion under 
normal and low dietary Mg2+ availability 
 To study the effect of omeprazole on serum Mg2+ levels as well as 24-h urinary and 
fecal excretion of Mg2+, mice were treated with 20 mg/kg body weight omeprazole (or vehicle) 
via oral gavage once a day. Serum Mg2+ levels, 24-h urinary Mg2+ excretion as well as 24-h 
fecal Mg2+ excretion were determined at the start of the experiment and after 28 days of 
treatment.  There were no significant differences in body weight, food and water intake, 
diuresis, and fecal weight between the omeprazole-treated mice and vehicle-treated controls 
(P > 0.2 for all parameters) during their stay in the metabolic cages (Table 2). 
 
Table 2 Characteristics of vehicle-treated controls and omeprazole-treated mice. 
 
Serum Mg2+ levels (Figure 1A) were unaltered in omeprazole-treated mice compared 
to the vehicle-treated controls (1.48 ± 0.05 mmol/L and 1.54 ± 0.05 mmol/L in omeprazole-
treated versus vehicle-treated mice, respectively, P > 0.2). The urinary excretion of Mg2+ 
(Figure 1B) did not significantly differ between the omeprazole group and the control group 
(35 ± 3 µmol/24 h and 30 ± 4 µmol/24 h for omeprazole-treated and vehicle-treated mice, 
respectively, P > 0.2). In addition, fecal Mg2+ excretion (Figure 1C) was not significantly 
different in omeprazole-treated mice compared to the vehicle-treated controls (76 ± 4 
µmol/24h and 84 ± 4 µmol/24 h in omeprazole-treated and control mice, respectively, P > 
0.2). 
 
   Controls Omeprazole 
Body weight (g) 30.1 ± 0.9 30.2  ± 1.1 
Food intake (g/24 h) 3.1  ± 0.2 3.0  ± 0.3 
Water intake (mL/24 h) 4.2  ± 0.3 4.2  ± 0.2 
Diuresis (mL/24 h) 1.2  ± 0.2 1.4  ± 0.2 
Fecal weight (g/24 h) 1.6  ± 0.2 1.5  ± 0.2 
Values are given ± SEM 
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Figure 1. Effect of omeprazole treatment on Mg2+ homeostasis in CB57BL/6J mice. A. Serum Mg2+ 
concentration B. 24-h urinary Mg2+ excretion and C. 24-h fecal Mg2+ excretion in vehicle-treated 
controls (white bars) and omeprazole-treated mice (black bars) are shown. Data are presented as 
means ± SEM. 
 
 To determine whether the effect of omeprazole on Mg2+ homeostasis is influenced 
by dietary Mg2+ availability, a subsequent experiment was performed in which mice were fed 
a Mg2+-deficient diet in addition to the treatment with omeprazole or vehicle. This diet 
induced a significant decline in serum Mg2+ values; however, no differences were observed 
between omeprazole- and vehicle-treated mice after 8 or 20 days of treatment (Figure 2). After 
22 days on the Mg2+-deficient diet, the animals were reintroduced to a diet with normal Mg2+ 
content, to investigate the recovery rate between the two groups of mice. Within 2 days serum 
Mg2+ levels normalized to baseline values with no differences between omeprazole-treated 
animals and controls (1.42 ± 0.02 mmol/L and 1.44 ± 0.02 mmol/L for omeprazole-treated and 
vehicle-treated controls, respectively, P > 0.2). 
 
 
A B C 
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Figure 2. Effects of dietary Mg2+ restriction and omeprazole on serum Mg2+ in CB57BL/6J mice. Vehicle-
treated controls (white bars) and omeprazole-treated mice (black bars) were fed a Mg2+-deficient diet 
(0.02% w/w Mg2+) for 22 days and then switched to a normal diet (0.2% w/w Mg2+) to monitor recovery. 
*, # P < 0.05 compared to the corresponding group on day 0. 
 
Effect of omeprazole treatment on gastric pH  
  To confirm the effect of omeprazole treatment on gastric acid secretion in our mouse 
model, we measured the pH in the gastric lumen using pH indicator strips (Figure 3). 
Four hours after administration of omeprazole, the intragastric pH was pH 6.7 ± 0.2 indicating 
that gastric acid production was effectively inhibited by omeprazole. Twenty-eight hours after 
the last dose of omeprazole was administered, the stomach pH remained significantly elevated 
with a pH 4.4 ± 0.4 in omeprazole-treated mice compared to a pH of 2.6 ± 0.3 in vehicle-
treated mice (P < 0.05). These findings indicate that the omeprazole treatment ensured a 
continuous suppression of gastric acid secretion throughout the experiment. 
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Figure 3. Effects of omeprazole treatment on gastric acid production. Effect of omeprazole treatment on 
gastric pH, 4 or 28 h (black bars) after administration of the last dose. Data are presented as means ± SEM. 
* P < 0.05 compared to vehicle-treated controls (white bars).  
 
 
Co-expression of TRPM6 and colonic H+,K+-ATPase in the colon 
To confirm the co-localization of TRPM6 and cHK-α, their mRNA expression levels were 
determined in a murine gastrointestinal tissue panel (Figure 4).  
 
 
 
 
 
Figure 4. Gastrointestinal expression pattern of TRPM6 and cHK-α mRNA. mRNA expression levels of 
TRPM6 (black bars) and cHK-α (white bars) in the different segments of the gastrointestinal tract of 
CB57BL/6J mice as determined by real-time PCR. Expression levels are shown as a percentage of total 
gastrointestinal expression and were corrected for GAPDH expression. Data are presented as means ± 
SEM. 
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TRPM6 mRNA expression was found predominantly in the caecum and throughout the colon, 
while expression levels in the duodenum were negligible. cHK-α mRNA expression was low in 
the duodenum and caecum whereas in the colon, expression increased from the proximal 
towards the distal end.  
 
Omeprazole treatment specifically enhances mRNA expression of TRPM6 and cHK-α in the 
colon  
Next, we investigated whether omeprazole affected TRPM6 and cHK-α mRNA 
expression levels in the colon (Figure 5A and B). Since the mRNA expression of both genes 
overlaps in the proximal as well as the distal colon, TRPM6 and cHK-α mRNA expression 
levels were analyzed in both colonic segments, to determine if they are affected by 
omeprazole treatment. The expression of TRPM6 in the proximal segment of the colon was 
not significantly increased (127 ± 17% and 100 ± 4% in omeprazole-treated and control 
mice, respectively, P > 0.2). There was, however, a significant upregulation of cHK- in 
omeprazole-treated mice compared to vehicle-treated controls (257 ± 55% and 100 ± 7% in 
omeprazole-treated and control mice, respectively, P < 0.05). 
In the distal colon, the expression level of TRPM6 mRNA was increased ~1.5 times in 
omeprazole-treated mice compared to the vehicle-treated controls (167 ± 15% and 100 ± 7% 
for omeprazole-treated and vehicle-treated mice, respectively, P < 0.05). Similar to our 
findings in the proximal colon, cHK-α mRNA expression levels in the distal colon were ~3.5 
times higher in omeprazole-treated mice compared to controls (354 ± 43% and 100 ± 24% 
for omeprazole-treated and vehicle-treated mice, respectively, P < 0.05).  
In the kidney (Figure 5C), TRPM6 mRNA expression was significantly lower in 
omeprazole-treated mice compared to the controls (89 ± 4% and 100 ± 1% for omeprazole-
treated and vehicle-treated mice, respectively, P < 0.05). The levels of cHK-α mRNA were 
unaltered by the omeprazole treatment (112 ± 22% and 100 ± 3% for omeprazole-treated 
and vehicle-treated mice, respectively, P > 0.2).  
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Figure 5. Effects of omeprazole treatment on mRNA expression levels of various magnesiotropic genes 
and H+-K+-ATPases in the colon and kidney. Relative mRNA expression levels (corrected for GAPDH) of 
TRPM6 and cHK-α in vehicle-treated controls (white bars) and omeprazole-treated mice (black bars) in A 
the proximal and B the distal colon, as well as in C the kidney. D Expression levels of various 
magnesiotropic genes and the gHK-α in the distal colon of vehicle-treated controls and omeprazole-
treated mice. Data are presented as means ± SEM, * P < 0.05 compared to vehicle-treated controls. 
 
 The mRNA expression levels of magnesiotropic genes other than TRPM6 could 
function as important negative controls as they could demonstrate the specificity of the 
upregulation of TRPM6 and cHK-α in the colon in reaction to omeprazole treatment. 
Therefore, we determined the expression levels of the following well-known magnesiotropic 
genes in the distal colon of omeprazole- and vehicle-treated mice: TRPM7, epidermal growth 
factor (EGF), EGF receptor (EGFR), potassium voltage-gated channel subfamily A member 1 
(Kv1.1), Cyclin M2 (CNNM2) and hepatocyte nuclear factor 1 homeobox B (HNF1B) (Figure 5D). 
A B C 
D 
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 The mRNA expression level of TRPM7, the closest homologue of TRPM6 and 
therefore the most important negative control, was unaltered in the distal colon of 
omeprazole-treated mice compared to the expression in vehicle-treated controls (104 ± 7% 
and 100 ± 3% for omeprazole-treated and vehicle-treated mice, respectively, P > 0.2). The 
expression levels of the other tested magnesiotropic genes were also not significantly altered 
by omeprazole treatment. In addition to the magnesiotropic genes, we have also analyzed the 
expression levels of the gHK-. There was a small but significant increase in the expression of 
gHK- in omeprazole-treated mice versus vehicle-treated controls (148 ± 15% and 100 ± 2% 
in omeprazole-treated and control mice, respectively, P < 0.05). 
 
 
Discussion 
 This study demonstrates for the first time that omeprazole treatment enhances the 
colonic expression levels of both TRPM6 and cHK-α mRNA suggesting that omeprazole 
indeed influences intestinal Mg2+ absorption. However, prolonged exposure to omeprazole 
had no effect on either serum Mg2+ levels, urinary Mg2+ excretion, or fecal Mg2+ excretion in 
C57BL/6J mice under normal or low dietary Mg2+ conditions. Moreover, omeprazole did not 
affect the development of hypomagnesemia under dietary Mg2+ restriction, nor the recovery 
from hypomagnesemia under normal dietary Mg2+ conditions.  
 Under conditions of normal dietary Mg2+ availability, the majority of intestinal Mg2+ 
absorption takes place in the small intestine via a passive, paracellular pathway. When dietary 
Mg2+ concentrations are low, or when bodily needs are high, active transcellular transport via 
TRPM6 becomes more important.28 By performing our experiments both under normal and 
low dietary Mg2+ availability, we aimed to distinguish between the effect of omeprazole on 
the paracellular and transcellular absorption pathways. Although there was no effect of 
omeprazole treatment on serum Mg2+ levels nor on urinary and fecal Mg2+ excretion, there 
was a significant increase in both TRPM6 and cHK-α mRNA levels in the distal colon of 
omeprazole-treated mice. The difference in the effect of omeprazole on TRPM6 mRNA 
expression in the proximal and distal colon is most likely the result of the lower baseline cHK-
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 expression in the proximal segment (as shown in figure 4), the net increase in cHK- 
expression is therefore much lower in the proximal colon, consequently resulting in a less 
robust effect on TRPM6. The mRNA expression levels of several other known magnesiotropic 
genes, including the TRPM6 homologue TRPM7, were not affected, indicating that the effect 
of omeprazole treatment on TRPM6 expression in the colon is highly specific.  
 In addition to the effect in the colon, omeprazole treatment also slightly decreased 
TRPM6 mRNA expression in the kidney; however, the renal expression of cHK-a remained 
unchanged. Importantly, the unaltered urinary Mg2+ excretion of the mice indicates that the 
final renal Mg2+ balance was not compromised by the slight decrease of renal TRPM6 
expression.  
 The increased expression of cHK-α mRNA in the colon upon treatment with 
omeprazole was very distinct. We also found a small, but statistically significant, increase in 
gHK-α mRNA expression in the distal colon of omeprazole-treated mice compared to the 
vehicle-treated controls. The expression levels of gHK- in the colon are, however, very low, 
so the functional relevance of this small increase is disputable. Previous studies have described 
an increase in mRNA expression level of the gHK- in the stomach induced by omeprazole 
treatment 29. Most likely, the increased mRNA levels of the H+,K+-ATPases in the colon 
represent an adaptation mechanism to restore acid secretion. There is clear evidence from in 
vivo models that omeprazole can indeed accumulate in the colonic epithelium, although this 
accumulation is not as strong as in the stomach.30, 31  
As described before, omeprazole is a lipophilic pro-drug which easily passes the 
plasma membrane. In the presence of protons, the pro-drug is converted into an active form, 
trapping it into the cell. The conversion of the PPI, which causes its accumulation in the cell, 
also enables the binding of the PPI to intracellular cystein residues of the gHK-α, thereby 
inhibiting the extrusion of protons.32 The fact that omeprazole accumulates in the colon 
indicates that the colonic cells have a sufficiently low pH to allow for omeprazole activation, 
potentially leading to inhibition of cHK-α. The function and pharmacological sensitivity of the 
various HK-αs depends on the species, tissues, and systems in which they are studied.33, 34 The 
inhibitory effect of omeprazole on cHK-α was shown in fractionized membranes of guinea pig 
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distal colon, in which omeprazole was found to reduce cHK-α activity by 30%.26 Furthermore, 
studies in Ussing chambers indicated that omeprazole inhibits cHK-α activity in the colon.27 
Inhibition of cHK-α by omeprazole would lead to a reduction of proton secretion into the 
lumen of the colon. Importantly, it has been shown that extracellular protons enhance inward 
currents via TRPM6, indicating that Mg2+ influx via TRPM6 is strongly dependent on the 
extracellular pH.24 We therefore hypothesized that the effect of omeprazole on intestinal Mg2+ 
absorption is the result of an indirect effect of omeprazole on TRPM6, elicited via the reduction 
of cHK-α-mediated proton secretion. This hypothesis is in line with findings from previous 
studies which show that fermentable substrates, such as carbohydrates, stimulate intestinal 
Mg2+ absorption.35 The fermentation of these substrates by bacteria leads to an acidification 
of the caecum and colon, without influencing systemic acid/base homeostasis. Interestingly, 
increasing the amount of fermentable substrate in the food results in increased intestinal Mg2+ 
absorption, whereas the absorption of other minerals such as calcium, iron, and zinc remains 
unchanged. Several human studies have confirmed the enhancing effect of fermentable oligo- 
or polysaccharides on Mg2+ absorption.35 These findings are in line with our hypothesis that 
changes in pH can influence Mg2+ absorption in the colon. 
 A tissue panel of the mouse intestinal tract shows abundant TRPM6 mRNA expression 
in the caecum as well as the colon, which is in line with earlier observations from our group.23 
cHK-α mRNA expression was predominantly found in the colon, where its expression increases 
towards the distal end, that is in accordance with the fact that active potassium absorption 
predominantly takes place in the distal part of the colon.36 The co-expression of TRPM6 and 
cHK-α along the entire colon supports our hypothesis. The concurring upregulation of TRPM6 
and cHK-α mRNA expression could represent a compensatory mechanism aiming to maintain 
sufficient Mg2+ absorption by counteracting the inhibitory effects of omeprazole on cHK-α-
mediated proton secretion and TRPM6-mediated Mg2+ absorption. This would explain the lack 
of an effect of omeprazole on serum Mg2+ levels as well as urinary and fecal Mg2+ excretion 
in our mouse model.  
 Recently, a mathematical model simulating intestinal Mg2+ absorption has been 
described, aiming to explain PPIH. According to this model, PPI treatment reduces Mg2+ 
absorption, leading to a 5% decrease of serum Mg2+.37 In a study with healthy volunteers, 
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administration of omeprazole (40 mg) once a day for 7 days reduced Mg2+ absorption by 1%.38 
Bai et al. showed that a 1% reduction of Mg2+ absorption could lead to an 80% depletion of 
Mg2+ stores over the course of 1 year. The minute changes described might go undetected in 
clinical practice or experimental conditions but could, over longer periods, result in PPIH. This 
is in line with the fact that most PPIH patients described so far are indeed long-term (>1 year) 
PPI users.5 
Several questions concerning the development of PPIH in human patients remain 
unanswered. The incidence of PPIH is still unknown, although there are indications that the 
case reports only represent the tip of the iceberg. 17 A simple explanation may be found in the 
dietary intake of Mg2+; as the changes in Mg2+ absorption due to omeprazole treatment are 
small, they are easily corrected by a higher intake of Mg2+, which could explain why certain 
patients develop PPIH whereas others do not.37 The low incidence could, however, also 
indicate that patients will only develop PPIH if they are in some way predisposed. For example, 
a recent study shows a strong correlation between PPIH and the combined use of PPIs and 
diuretics.39 Another possibility, outlined in case reports, is that the presence of mutations or 
single-nucleotide polymorphisms (SNPs) in magnesiotropic genes such as TRPM6 contributes 
to the development PPIH. In a single case of PPIH, TRPM6 was sequenced, but no 
abnormalities were found in exonic regions of TRPM6.8 Another study excluded the presence 
of mutations in SLC12A3, which is one of the genes involved in Gitelman syndrome.12 However, 
these individual cases do not exclude the involvement of SNPs in magnesiotropic genes, and 
larger studies are needed in order to confirm or exclude the involvement of predisposing 
factors in the development of PPIH.  
In conclusion, this study provides new insights in the effect of omeprazole on Mg2+ 
homeostasis in an in vivo setting, which could potentially shed light on the molecular aspects 
of the etiology of PPIH. A significant and specific effect of omeprazole treatment on TRPM6 
and cHK-α mRNA expression levels in the distal colon was found, while the serum Mg2+ levels, 
24-h urinary Mg2+ excretion as well as 24-h fecal Mg2+ excretion were not affected. The 
stimulation of mRNA levels was distinct in the colon, whereas in the kidney, little or no changes 
occurred. This is in line with the clinical findings indicating that PPIH results from reduced 
intestinal Mg2+ absorption and not from renal Mg2+ wasting. Further research, both on a 
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clinical as well as a fundamental level, is needed to fully understand and prevent PPIH in the 
near future. 
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Abstract 
Proton-pump inhibitor-induced hypomagnesemia (PPIH) is the most recognized side 
effect of proton-pump inhibitors (PPIs). Additionally, PPIH is associated with secondary 
hypocalcemia and hypokalemia. It is hypothesized that PPIs reduce epithelial proton secretion 
and thereby increase the pH in the colon, which may explain the reduced absorption of and 
Mg2+ and Ca2+. Fermentation of dietary oligofructose-enriched inulin fibers by the microflora 
leads to acidification of the intestinal lumen and by this enhances mineral uptake. This study 
aimed, therefore, to improve mineral absorption by application of dietary inulin to counteract 
PPIH. 
Here, C57BL/J6 mice were supplemented with omeprazole and/or inulin. 
Subsequently, Mg2+ and Ca2+ homeostasis was assessed by means of serum, urine and fecal 
electrolyte measurements. Moreover, the mRNA levels of magnesio- and calciotropic genes 
was examined in the large intestine and kidney by real-time PCR. 
Treatment with omeprazole significantly reduced serum Mg2+ and Ca2+ levels. 
However, concomitant addition of dietary inulin fibers normalized serum Ca2+ but not serum 
Mg2+ concentrations. Inulin abolished enhanced expression of the genes Trpv6 and S100g by 
omeprazole. Additionally, intestinal and renal mRNA levels of the magnesiotropic Trpm6 gene 
were reduced after inulin intake. 
This study suggests that dietary inulin counteracts reduced intestinal Ca2+ absorption 
upon PPI treatment. In contrast, inulin did not increase intestinal absorption of Mg2+ 
sufficiently to recover serum Mg2+. The clinical potential of dietary inulin treatment should be 
the subject of future studies. 
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Introduction 
Since their introduction two decades ago, proton pump inhibitors (PPIs) became the 
mainstay in gastro esophageal reflux (GERD), peptic ulcer disease (PUD), persistent non-
steroidal anti-inflammatory drug (NSAID) treatment and generalized dyspepsia (heartburn).1-
3 PPIs form a class of drugs that is widely prescribed, with millions of chronic users world-
wide.4 The most recognized side effect of all marketed PPIs is proton-pump inhibitor-induced 
hypomagnesemia (PPIH).5, 6 First described in 2006, thereafter many single case-reports and 
small case-series on the subject emerged.7-9 The U.S. Food- and Drug Administration (FDA) 
issued a warning in 2011 and the critical assessment of their adverse events databank showed 
that more cases exist than previously was assumed.10 It is widely anticipated that PPIH is the 
consequence of intestinal Mg2+ malabsorption, since a renal leak was never detected.6, 11 An 
underappreciated aspect of PPIH are frequent secondary electrolyte disturbances such as 
hypocalcemia and hypokalemia.8, 12, 13 However, the clinical significance of reduced calcium 
(Ca2+) levels has been emphasized by several dozens of studies showing increased risk of bone 
fractures after chronic PPI use.14 
The exact mechanism by which PPIs cause mineral deficits is currently under debate. 
Recent in vitro data suggests that omeprazole inhibits passive paracellular Mg2+ fluxes, 
predominantly present in the small intestine.15, 16 Moreover, in vivo studies indicate that 
omeprazole directly interferes with important transcellular Mg2+ transport mechanisms of the 
colon.17 In the tight epithelium of colon, the epithelial Mg2+ channel, transient receptor 
potential melastatin member 6 (TRPM6), facilitates the absorption of Mg2+.18-20 Omeprazole 
specifically enhances the mRNA levels of Trpm6 as well as Atp12a, which encodes the non-
gastric proton potassium adenosine triphosphatase (colonic H+,K+-ATPase or cHK-α).17 It has 
been suggested that omeprazole locally inhibits the cHK-α, leading to a raise in pH of the 
colon.17 Given that TRPM6-mediated Mg2+ transport is dependent on the protonation of the 
channel itself, PPI-induced pH increases will reduce TRPM6-mediated Mg2+ influx.21-23 
To date, defined intervention strategies preventing PPIH do not exist in clinical 
practice. Local luminal acidification of the colon may rescue intestinal Mg2+ absorption and, 
therefore, provides a promising approach to prevent PPIH. Interestingly, the dietary 
application of the fructan fiber inulin has been proposed to reduce intestinal pH.24 Ingested 
inulin fibers are fermented in the large intestine by bifidogenic gut bacteria, resulting in short-
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chain fatty acids (SCFA), which in turn acidify the colon.25 The stimulating action of SCFA on 
intestinal Mg2+ absorption by lowering the pH has already been described decades ago, but 
has been largely overlooked since then.26, 27 However, inulin fibers have been shown to 
stimulate Mg2+ and Ca2+ absorption in the colon of mice and humans.28, 29 Moreover, inulin 
fibers are capable of directly modulating intestinal and renal Trpm6 mRNA expression.30 
Here, an intervention study was performed using dietary oligfructose-enriched inulin 
fibers in control- and omeprazole-treated wildtype C57BL/6J male mice. The aim was to 
enhance intestinal Mg2+ and Ca2+ absorption in order to counteract omeprazole-induced 
defects in mineral uptake. Additionally, the mRNA expression patterns of the Mg2+ and Ca2+ 
transporting proteins expressed in the cecum, colon and kidney were scrutinized. 
 
Materials and Methods 
Animal studies 
This study was carried out in strict compliance with the legal Dutch animal welfare 
act. All experimental procedures were approved by the animal ethics board of the Radboud 
University Nijmegen (permit-no: RU-DEC 2014-032) and all efforts were made to minimize 
suffering of the animals. Wild-type C57BL/6J mice (n=40 males, 9 weeks old) were purchased 
from Charles River, the Netherlands. The animals were randomly allocated into 4 experimental 
groups of n=10 mice. Before the experiment was started, the animals underwent 
acclimatization for 1 week under temperature- and light-controlled conditions with ad-libitum 
access to standard pellet chow (SSNIFF Spezialdiäten GmbH, Germany) and drinking water. 
The control diet consisted of standard pellet chow, the experimental inulin diet additionally 
contained 10% (w/w) inulin fiber product (Orafti Synergy1, Beneo-Orafti, Belgium). 
Omeprazole (Fagron, the Netherlands) was dispersed in a solution (vehicle) containing 0.5% 
(w/v) methylcellulose and 0.2% (w/v) NaHCO3 (adjusted with NaOH to pH 9.0). During the 14 
days of the experimental phase, the mice received a daily dose of 20 mg omeprazole per 
kilogram bodyweight, administered via oral gavage once a day, or vehicle. The health of the 
animals was regularly checked. For urine and feces collection, animals were housed solitarily 
in metabolic cages for 24 h. At the experimental endpoint, animals were anesthetized with 
isoflurane, blood sampling was performed by orbital sinus bleeding and subsequently the 
mice were sacrificed by cervical dislocation. Kidneys, cecum and colon segments were 
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extracted and cleaned, fecal contents of cecum and colon were preserved and all samples were 
snap frozen in liquid nitrogen. 
 
Analytical procedures 
Serum Mg2+, Ca2+, K+ and Na+ were determined at the university hospital central 
clinical lab on an automated system according to the manufacturer's protocol (Abbott 
Diagnostics, Belgium). Feces were homogenized and digested in nitric acid (concentrated with 
65 % (w/w) Sigma-Aldrich, USA) by a 2 h pre-incubation at 50 °C, followed by an overnight 
incubation at room temperature. Urinary and fecal Mg2+ concentrations were determined with 
a colorimetric xylidyl-II blue kit (Cobas Roche Diagnostics, UK) on a Nanodrop 2000c 
spectrophotometer (Thermo Fisher Scientific, USA) at 600 nm wavelength. Urinary and fecal 
Ca2+ concentrations were spectrometrically determined with a colorimetric 
chromogenic/buffer dual-component kit (Sigma Aldrich, UK) on a Biorad plate reader (Biorad, 
USA) at 570 nm wavelength. The obtained values for Mg2+ and Ca2+ were cross verified using 
a serum standard solution (Precinorm U, Roche, Switzerland). 
 
Quantitative real-time PCR 
Total RNA was extracted from tissues using TRIzol reagent (Invitrogen, UK) according 
to the manufacturer’s protocol. Obtained RNA was subjected to DNase treatment (Promega, 
USA). Subsequently, the purified RNA was reverse transcribed with murine leukemia virus 
reverse transcriptase (Invitrogen, the Netherlands). The mRNA expression was quantified by 
SYBR Green (BioRad, USA) real-time PCR on a CFX96 real-time detection system (BioRad, USA). 
Real-time PCR primers (Biolegio, the Netherlands) were designed with Primer 3 software 
(Whitehead Institute for Biomedical Research, USA). Primer sequences are provided in S1 
Table. Obtained mRNA levels were normalized by glyceraldehyde 3-phosphate 
dehydrogenase (Gapdh) as an endogenous control. Relative mRNA expression was analyzed 
according to the Livak method (2 -∆∆cT) and annotated as times-fold change of expression 
compared to control.31 
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Statistics 
Values are expressed as means ± SEM. The differences between single groups of 
control, inulin-only, omeprazole-only and omeprazole + inulin treated mice were tested by 
using one-way ANOVA with a Tuckey correction. Differences between groups were regarded 
to be statistically significant when P < 0.05. The analysis of the datasets was performed using 
GraphPad Prism (PC version 6).  
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Results 
Omeprazole treatment results in reduced serum Mg2+ 
In this study, we aimed to evaluate the application of dietary oligofructose-enriched 
inulin fibers as a means to prevent PPIH. Therefore, wildtype C57BL6/J mice were 
supplemented with vehicle or omeprazole for 14 days. In addition, the vehicle group and the 
omeprazole group were subdivided into two groups fed with a normal diet or with a diet 
containing 10% w/w oligofructose-enriched inulin fructan fibers, making a total of four 
experimental groups (Table 1). After 14 days of experimental procedure, the mean bodyweight 
of the animals was equal (Table 1). Compared to the control group, food intake, water intake 
and diuresis did not change due to omeprazole or inulin treatment. The mean fecal output of 
the inulin-omeprazole-treated group was significantly elevated compared to mice receiving 
only omeprazole (1.5 ± 0.2 g and 1.05 ± 0.06 g, respectively, Ρ < 0.05). 
 
Table 1. Metabolic parameters of the animals 
The results are expressed as means ± SEM (n=10). Significant differences between the two 
omeprazole-treated groups are indicated by # with P < 0.05. Mice stayed on normal diet or on a 
diet containing 10% (w/w) oligofructose enriched inulin fibers. Treated mice received 20 mg/kg 
bodyweight omeprazole. 
 
To study the effect of omeprazole and a possible combinatory effect of the inulin diet 
on Mg2+ homeostasis, serum Mg2+ concentration, 24 h urinary Mg2+ and fecal Mg2+ excretion 
were determined. Omeprazole-treated and inulin-omeprazole-treated mice had significantly 
   Control Inulin Omeprazole Inulin-Omeprazole 
Diet  normal inulin normal inulin 
Omeprazole treatment  vehicle vehicle omperazole omeprazole 
  Mean   SEM Mean SEM Mean SEM Mean SEM 
Body weight (g) 23.8  0.4 24.2  0.5 24.0  0.4 23.7  0.4 
Food intake (g/24h) 3.8 0.3 4.2 0.2   3.2# 0.2 4.2 0.2 
Fecal dry weight (g/24h)  1.13  0.06  1.26  0.05  1.05  0.06  1.5# 0.2 
Water intake (mL/24h) 3.9 0.4 4.1 0.1 3.9 0.4 4.1 0.4 
Diuresis (mL/24h)  1.30  0.07  1.38  0.10  1.02  0.11  1.23  0.08 
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lower serum Mg2+ levels compared to control mice ((1.26 ± 0.03 mmol/L, 1.23 ± 0.04 mmol/L) 
and 1.39 ± 0.02 mmol/L, respectively, P < 0.05 Figure 1A). Urinary Mg2+ excretion was 
significantly increased in the inulin-omeprazole group compared to omeprazole-treated 
group (1.0 ± 0.1 mmol/L and 1.23 ± 0.08 mmol/L, respectively, Ρ < 0.05 Figure 1B). Fecal Mg2+ 
excretion was equal among all groups (Figure 1C). 
 
 
 
 
 
 
Figure 1. Effects of inulin diets and omeprazole treatment on the Mg2+ homeostasis of C57BL/6J mice. 
Serum Mg2+ concentration (A), 24 h urinary Mg2+ excretion (B) and 24 h fecal Mg2+ excretion (C). All values 
are presented as means ± SEM (n=10 per group). Significant differences between control vs. both 
omeprazole groups are indicated by * with P < 0.05, significant differences within omeprazole groups are 
denoted by # with P < 0.05. 
 
Dietary inulin reduces the expression of Trpm6 
To identify the effect of omeprazole treatment and inulin-enriched diets, the mRNA 
levels of genes involved in Mg2+ transport were evaluated. In cecum, addition of inulin to the 
diet significantly reduced Trpm6 mRNA levels by 32 ± 7% compared to vehicle-treated mice 
on the normal diet and by 40 ± 3% in mice that received inulin combined with omeprazole 
(Figure 2A). In colon, the Trpm6 mRNA levels were not significantly different between the 
groups (Figure 2B). Accordingly, Trpm6 mRNA levels were reduced by 29 ± 5% in the inulin 
group compared to the control group, and the mice of the inulin-omeprazole group had 29 ± 
4% lower Trpm6 mRNA levels compared to the omeprazole only treated mice (Figure 2C). 
 
 
A B C 
Inulin prevents PPI-induced hypocalcemia 
63 
 
 
 
 
 
 
 
 
Figure 2. Effects of omeprazole treatment and diets enriched with 10% (w/w) inulin on mRNA levels of  
 
PPIH candidate genes. Expressional levels of Trpm6 and Atp12a, encoding the non-gastric H+,K+-ATPase 
in cecum (A + D), colon (B + E) and kidney (C + F) of C57BL/6J mice compared to control (corrected for 
Gapdh expression). Significant differences compared to control are indicated by * with P < 0.05, significant 
differences within the omeprazole-treated mice are annotated by # with P < 0.05. All values represent 
means ± SEM, with n=10 mice per group. 
 
Besides Trpm6, the expression of the non-gastric H+,K+-ATPase encoded by Atp12a 
was assessed (Figures 2D-F). Inulin reduced Atp12a mRNA levels from 149 ± 12% in the 
omeprazole-only group down to 58 ± 14% in the inulin-omeprazole group (Figure 2D). In 
colon and in kidney there were no significant differences present (Figures 2D-E). 
 
Dietary inulin rescues omeprazole-induced low serum Ca2+ 
Serum Ca2+ of the omeprazole-treated mice was slightly, but, significantly reduced 
compared to the vehicle-treated control group (2.19 ± 0.01 mmol/L and 2.27 ± 0.01 mmol/L, 
respectively, P < 0.05, Figure 3A).  
 
A B C 
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Figure 3. Effects of the combinatory application of omeprazole and 10% inulin enriched diets on 
electrolytes. Serum Ca2+ concentration (A), 24 h urinary Ca2+ excretion (B), 24 h fecal Ca2+ excretion (C), 
serum K+ concentration (D) and serum Na+ concentration (E). Significant differences compared to control 
are indicated by * with P < 0.05. Bars represent means ± SEM, with n=10 mice per group. 
 
The application of the inulin diet under omeprazole resulted in a correction of serum 
Ca2+ to the level of control mice and inulin-only treated mice. This is reflected in the 24 h 
urinary Ca2+ excretion; omeprazole treated mice displayed a reduced urinary Ca2+ excretion 
compared to the mice on the inulin diet 2.7 ± 0.3 µmol/24 h and 4.3 ± 0.5 µmol/24 h, 
respectively, P < 0.05 Figure 3B). The fecal excretion of Ca2+ in all groups was significantly 
lower compared to control mice (for inulin 0.55 ± 0.03 mmol/24 h, for omeprazole 0.48 ± 0.03 
mmol/24 h, for inulin-omeprazole 0.55 ± 0.03 mmol/24 h vs. control 0.93 ± 0.07 mmol/24 h, 
Figure 3C). The serum K+ level of the inulin-omeprazole group was significantly lower than 
that of the control group (4.8 ± 0.1 mmol/L and 5.08 ± 0.05 mmol/L, respectively, P < 0.05, 
Figure 3D). There were no significant differences in serum Na+ levels observed (Figure 3E). 
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Inulin prevents PPI-induced upregulation of calciotropic genes 
In order to investigate if the treatment regimens induced differential gene regulation, 
the mRNA levels of the main calciotropic genes in the intestine, Trpv6 together with S100g 
and, Trpv5 and Calb1 expressed in the kidney were quantified. In cecum no significant 
differences were observed for Trpv6 mRNA levels within the respective diet groups, however 
in colon Trpv6 expression was significantly increased to 170 ± 14% compared to the control 
group (Figures 4A-B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Effects of omeprazole and 10% inulin-enriched diets on mRNA expression levels of the 
calciotropic genes. Trpv6 and S100g mRNA in cecum (A + D), colon (B + E) and mRNA of Trpv5 and Calb1 
in the kidney (C + F), corrected for Gapdh and normalized to control. Significant differences compared to 
control are indicated by * with Ρ < 0.05, significant differences compared to the omeprazole-treated group 
are annotated by # with P < 0.05. All values represent means ± SEM, with n=10 mice per group.  
 
Addition of inulin completely abolished this increase. In the kidney Trpv5 mRNA levels 
of both omeprazole-treated groups were not significantly different from the respective control 
groups on normal diets. In the intestine, the expression pattern of S100g was similar in cecum 
A B C 
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and colon. In both segments, the mRNA levels in omeprazole-only treated mice were 
significantly increased compared to all the other groups (Figures 4D-E). In cecum, S100g 
mRNA levels were increased to 284 ± 32% compared to the control group and in colon to 291 
± 24%. In contrast, no significant differences were observed for the mRNA levels of Calb1 in 
the kidney (Figures 4F). 
Discussion 
This is the first study evaluating a treatment strategy for PPI-induced mineral 
disturbances in mice. Using dietary inulin fibers, the primary aim was to directly counteract the 
development of PPI-induced Mg2+ and Ca2+ deficits by improving mineral absorption in the 
large intestine. The present study confirmed that dietary inulin stimulated the intestinal uptake 
of minerals, which prevented an omeprazole induced serum Ca2+ decrease. However, a 
correction of serum Mg2+ was not achieved by this approach. 
There is a large body of literature showing that dietary inulin fibers stimulate Mg2+ 
and Ca2+ absorption in rodents and humans.28, 32 The most potent stimulator of mineral 
absorption is a defined mixture of long- and short-chain oligofructose-enriched inulins, since 
certain strains of gut bacteria have a preference for inulin fibers based on chain length.33, 34 In 
accordance with several other studies, the inulin product was given at a 10% (w/w) dose added 
to regular chow.30, 35 In rats and mice it has been demonstrated that at this dose inulin induces 
luminal acidification in less than one week, enhancing solubilization of minerals and which 
subsequently result in osmotic attraction of water in the colon.34, 36 In this regard, it is 
important to note that a humidification of the feces of the inulin-treated mice was observed 
by present study, indicating that inulin activates bacterial fermentation also under omeprazole 
treatment. This suggests that reduced Atp12a mRNA levels in mice receiving inulin-enriched 
diets compared to the omeprazole-only treated were the result of inulin induced luminal 
acidification (Figures 2D). 
In our study, the mice on the normal diet showed a significant reduction of serum 
Ca2+ values due to omeprazole-treatment (Figures 3A). Importantly, concomitant application 
of dietary inulin prevented a drop in serum Ca2+ values under omeprazole treatment. A 
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pronounced reduction of intestinal Ca2+ absorption by PPIs has already been evidenced in 
early studies on PPIs and has been confirmed in recent reports.13, 37 To the authors knowledge, 
this is the first time that a treatment is successful to prevent PPI-induced Ca2+ disturbances. 
TRPV6 is the principal epithelial Ca2+ channel of the large intestine.38 It is constitutively open 
and selective for Ca2+ and its expression is highly regulated by the needs for intestinal Ca2+ 
absorption.39, 40 In cecum and in colon, omeprazole induced strong increases of intestinal 
Trpv6, together with its Ca2+-binding protein encoded by S100g in order to compensate for 
the impaired Ca2+ absorption and to correct reduced serum Ca2+ levels (Figures 4D-E). The 
addition of inulin completely abolished this increment, likely resulting from normalization of 
intestinal Ca2+ uptake, which is also reflected in normalized serum Ca2+ (Figure 4A) There is 
scarce in vitro data showing SCFAs directly enhance S100g mRNA levels, encoding CaBP9K.41 
However, direct effects of SCFA on gene expression were limited given the absence of 
increases in the inulin-only group. The absence of differences in renal Trpv5 and Calb1 
expression indicates that the effect of inulin can be primarily attributed to improved intestinal 
absorption of Ca2+. 
Despite the beneficial effect of dietary inulin supplementation on Ca2+ absorption, 
serum Mg2+ was still reduced in mice receiving combined omeprazole/inulin treatment. In the 
mouse, the intestinal Mg2+ uptake is mainly facilitated by the epithelial Mg2+ channel TRPM6 
that is predominantly expressed in cecum and colon.19 Interestingly, Trpm6 mRNA expression 
in cecum was significantly decreased in mice receiving inulin-enriched diets independently of 
the omeprazole treatment (Figure 2A). Because Trpm6 mRNA levels are inversely responsive 
to dietary Mg2+ availability, these findings suggest that dietary inulin stimulates intestinal Mg2+ 
absorption.42 For instance, in diabetic rats, which have reduced insulin-sensitivity and as a 
result reduced insulin-mediated stimulation of TRPM6, the mRNA expression of Trpm6 was 
increased compared to the non-diabetic controls.43 Moreover, in a previous study with 
omeprazole-treated mice, it has been suggested that increased Trpm6 expression 
compensates for reduced TRPM6 channel activity.17 Therefore, the reduced Trpm6 expression 
in cecum after inulin-treatment may indicate that inulin-treatment indeed stimulated the Mg2+ 
channel. This would be in line with previous studies showing increased TRPM6 currents in 
acidifying conditions.21 The fact that the inulin-induced stimulation of intestinal Mg2+ 
absorption does not reflect in restored serum values may be explained by insufficient urinary 
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Mg2+ retention. Urinary Mg2+ excretion was increased in mice receiving both inulin and 
omeprazole compared to mice treated with only omeprazole, which is reflected in a reduced 
expression of Trpm6 in the kidney. Although these findings are in line with previous 
experiments of Rondon and colleagues, reduced renal Mg2+ reabsorption is difficult to 
interpret given the low serum Mg2+ values.30 Because the nephron is devoid from any 
microbiota, inulin will not directly affect intratubular pH of the nephron. This is confirmed by 
the absence of effects of inulin on Atp12a expression in the kidney. However, SCFAs may have 
additional effects in the kidney that are poorly understood. Although recent studies have 
examined the effects of SCFAs in acute kidney injury (AKI) or hypertension, the role of SCFAs 
in renal electrolyte transport have never been investigated.44, 45 Our data suggest that SCFAs 
may affect Trpm6 expression in the kidney, independent of pH or serum Mg2+ values by an 
unknown mechanism. 
In our study, serum K+ values were reduced in omeprazole-treated animals and in 
mice receiving inulin and omeprazole treatment, following the same pattern as serum Mg2+ 
values. In the clinic, hypokalemia is often secondary to hypomagnesemia and frequently 
present in PPIH patients.5, 8, 12, 13 The general accepted hypothesis to explain this phenomenon 
is that hypomagnesemia results in increased K+ secretion in the nephron. Given that 
intracellular Mg2+ inhibits the renal ROMK K+ channel to reduce renal K+ secretion, 
hypomagnesemia may relieve this inhibition and increase K+ secretion.46 
The outcomes of our study highlight the need for reissuing the impact of PPIs on 
Ca2+ homeostasis, which recently got neglected by the clinical attention drawn by PPIH. Apart 
from secondary hypocalcemia due to PPIH, there is evidence suggesting isolated disturbances 
of Ca2+ homeostasis in PPI users.47, 48 Although, the exact underlying mechanisms are debated, 
it was anticipated that intestinal malabsorption is the causative factor, however long-term 
studies on the subject are missing.49, 50 Therefore, chronic users of PPIs belonging to a risk 
group, such as postmenopausal women should periodically undergo electrolyte screens in 
order to identify a possible impact of PPIs on Ca2+ absorption and to prevent depletion of 
bone storages. In conclusion, this in vivo study provides a potential treatment perspective for 
patients with PPI-induced mineral disturbances. Dietary oligofructose enriched inulin fibers 
prevented the omeprazole-induced reduction of Ca2+ absorption and improved intestinal 
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Mg2+ absorption in mice. Future clinical studies should investigate whether dietary inulin could 
prevent PPI-induced mineral deficits in patients. 
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Supporting Information 
S1 Table. Primer sequences used for real-time PCR analysis 
  NCBI ref. Forward primer (5'-3') Reverse Gene primer (5'-3') 
Gapdh NM_001289726.1 TAACATCAAATGGGGTGAGG GGTTCACACCCATCACAAAC 
Trpm6 NM_153417.1 AAAGCCATGCGAGTTATCAGC CTTCACAATGAAAACCTGCCC 
Atp12a NM_138652.2  GCTAAGGCAACGCGCGTCCT CTGTTTTCCGGCGCATACTGTGAC 
Trpv6 NM_022413.4 GGCCTCACAACCTCATTTAC CTCAATGAGCAGTCTAACAATC 
Trpv5 NM_001007572.2 CTCCGCCTTCCATCGAAGTTC GATGTCAGCTCCATGCTCAATG 
S100g NM_009789.2 CCTGCAGAAATGAAGAGCATTTT CTCCATCGCCATTCTTATCCA 
Calb1 NM_009788.4 AACTGACAGAGATGGCCAGGTTA TGAACTCTTTCCCACACATTTTGAT 
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Summary 
Background:  
Proton pump inhibitors (PPIs) are a mainstay therapy for all gastric acid related 
diseases. Clinical concerns arise from a small but growing number of case reports presenting 
PPI-induced hypomagnesemia (PPIH) as a consequence of long-term PPI use. Current opinion 
is that reduced intestinal magnesium absorption might be involved, but nothing is known on 
the molecular mechanism underlying PPIH. 
Aim:  
To investigate whether or not PPIH is a true, long-term drug-class effect of all PPIs 
and to scrutinize a possible role of comorbidity in its etiology. Therefore, the primary objective 
in particular was to investigate serum magnesium dynamics in trials drug withdrawal and re-
challenge. The secondary objective was to proﬁle the patient at risk. 
Methods:  
We reviewed systematically all currently available case reports on the subject and 
performed a statistical analysis on extracted data. 
Results:  
Proton pump inhibitor-induced hypomagnesemia PPIH is a drug-class effect and 
occurred after 5.5 years (median) of PPI use, onset was broad and ranged from 14 days to 13 
years. Discontinuation of PPIs resulted in fast recovery from PPIH in 4 days and re-challenge 
led to reoccurrence within 4 days. Histamine-2-receptor antagonists were the preferable 
replacement therapy in PPIH and prevented reoccurrence of hypomagnesemia. In PPIH no 
speciﬁc risk proﬁle was identiﬁed that was linked to the hypomagnesemia. 
Conclusions:  
The cases of PPIH show severe symptoms of magnesium depletion and identiﬁcation 
of its causation was only possible through withdrawal of the PPI. Clinical awareness of PPIH is 
key to avoid putting patients at risk. 
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Introduction 
Proton pump inhibitors (PPIs) were introduced onto the market for peptic ulcer disease 
in 1989. Today, they are the mainstay therapy in gastroesophageal reflux disease (GERD), 
gastritis and duodenal or gastric ulcers.1-4 Omeprazole is the prototype drug and it is still the 
most prescribed PPI worldwide. Since the introduction of omeprazole, other molecules have 
followed suit such as lansoprazole (1995), pantoprazole (1997), rabeprazole (1999) and 
esomeprazole (2001).5, 6  PPIs are highly effective and given the fact that a huge number of 
patients are in need for control of gastric acid made them to one of the top-selling 
pharmaceuticals of the last decade.7-9 PPIs have a number of side effects. Epidemiological 
studies have demonstrated that their use is associated with an increased risk for pneumonia, 
enteric microbial overgrowth and sepsis, although the attributed risk may be dependent on 
confounding factors.10-13 Clinical cross-sectional studies identified PPI use also to be 
associated with a higher risk of bone fracture, and in postmenopausal women the use of 
omeprazole was identified to be a risk factor for the incidence of vertebral fractures, 
independent from osteoporosis and age.14, 15 A directed retrospective data analysis of 
hospitalized patients identified PPI use to be associated with lower serum magnesium levels.16 
A few case reports, show the use of PPIs resulting in profound, but reversible, isolated 
hyponatremia, hypocalcemia and hypokalemia.17-24 And importantly, over the last 5 years 
several clinical case reports have been published that demonstrate PPI use to induce severe 
hypomagnesemia.25-42 PPI-induced hypomagnesemia (PPIH) leads to severe symptoms such 
as tetany, seizures, convulsions, cardiac arrhythmia and puts patients at risk for concomitant 
secondary electrolyte disturbances such as hypocalcemia. The cases are heterogenic and most 
patients have significant comorbidity and use multiple drugs. However, the molecular and 
physiological factors that may be involved in PPIH are not known. It is also not known, whether 
there are specific risk factors that contribute to PPIH. 
We, therefore, extensively re-evaluated the published literature on the subject. To 
investigate the dynamics of serum magnesium in relation to acute withdrawal and re-
challenge of PPIs, we performed a systematic analysis of all available case reports on the 
subject. In addition, we made an attempt to identify the nature and contribution of possible 
risk factors to PPIH. 
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Patients and Methods 
Literature review methods 
We reviewed the published cases on PPIH listed in MEDLINE (National Library of 
Medicine, Bethesda, MD) and PubMed published up to 1 December 2011. In addition, we 
performed an exhaustive search using Web of Knowledge and Google Scholar to uncover 
possibly missed case reports. We included all articles that were written in English, German, 
Dutch, French or Spanish language. All duplicates were removed. Two reviewers (M.H. and J.D.) 
independently evaluated the eligibility of all studies retrieved from the databases on basis of 
the predetermined selection criteria. Disagreements were resolved by discussion with a third 
party (J.H. and R.B.). To ensure that our search included all published articles, cross-citation 
screening was manually performed in the reference sections of included articles and within 
PubMed. We used the following MESH terms for our systematic search: hypomagnesemia, 
hypomagnesemia, PPI, proton pump inhibitor, pharmacology, pharmacokinetics, magnesium, 
omeprazole, pantoprazole, lansoprazole, rabeprazole, esomeprazole, H+,K+-ATPase, intestine, 
malabsorption, acid suppression, depletion, drug induced. 
Data extraction and analysis 
As we were interested in the course of serum magnesium levels in-patients receiving 
PPIs we focused on 2 clinical situations: (i) serum magnesium changes in relation to withdrawal 
of PPI; and (ii) serum magnesium levels in relation to re-challenge with PPI. Data from the 
reports were extracted from original text or tables and/or by digitizing the original published 
graphs. For digitizing the graphs we captured a high-resolution snapshot of the portable 
document ﬁle (PDF) with Adobe Photoshop CS3. To assure proper and reproducible digitizing, 
digitized measurement points were marked by crosshairs intercepting the center, and this 
template for digitizing was subsequently stored as high quality JPG image. Subsequently, each 
measurement point of the graphs was digitized three times by the ﬁrst author and by an 
independent colleague. Averages were pooled and the maximal point-to-point variation was 
2%. As a quality measure, we compared the original data obtained from two case reports with 
captured digitized data. This procedure revealed absence of signiﬁcant differences between 
either datasets. The timescale was always transformed into days. Further clinical data, such as 
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age, gender, PPI-type, doses (data not shown), symptoms due to hypomagnesemia co-
morbidity and medical history were extracted from the original text and/or tables. 
 
Biochemical data 
 Data were derived from the published case reports. To develop a comprehensive 
overview we obtained additional information using a structured questionnaire send to the 
ﬁrst/corresponding authors from six different case reports. We obtained additional patient 
data from three authors (refer to Acknowledgements). We designed an electronic data 
extraction form in MS Excel and used this for data entry. We extracted the following 
biochemical data from the case reports: serum magnesium, calcium, potassium and 
parathyroid hormone (PTH) (data not shown) as well as the urinary excretion of magnesium. 
The following cut-off values to indicate the severity of the electrolyte disturbances were used 
(all numbers in mmol/L): Hypomagnesemia was deﬁned by serum concentrations < 0.7 (mild) 
and severe (symptomatic) hypomagnesemia was deﬁned by a serum value of < 0.5. 
Hypocalcemia was categorized into three levels, mild hypocalcemia with plasma levels of 1.80–
2.10, moderate hypocalcemia 1.50–1.79 or severe hypocalcemia < 1.50. Mild hypokalemia was 
deﬁned by serum values of 3.1–3.5, moderate hypokalemia 2.5–3.0 or severe hypokalemia < 
2.5. 
 
Quality measures & demographical data 
 All cases were investigated for the causality between the administration of PPIs and 
hypomagnesemia evaluation of the case descriptions. From all case reports, data concerning 
age, gender, type, dosage and timescale of PPI usage, nadir of hypomagnesemia under PPI 
use, the calcium levels and the presence of hypokalemia, renal magnesium handling, serum 
magnesium after withdrawal/change in therapy and important medication and comorbidity, 
type of follow-up therapy and the use of magnesium supplementation were collected (partially 
shown in Table S1). 
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Study endpoints 
This review was guided by two endpoints.  
1. Primary goal was to investigate short-term changes of serum magnesium in selected
magnesium-depleted cases upon (i) withdrawal of the PPI (maximum 28 days); and (ii) at 
rechallenge with the PPI maximum (maximum 21 days). (i) In case of withdrawal we focused 
on the nadir of serum magnesium and the mean recovery time needed to reach 0.6 mmol/L 
after discontinuation of the PPI, as lower values hallmark symptomatic hypomagnesemia. (ii) 
In case of re-challenge we focused on the meantime needed for serum magnesium to intersect 
0.6 mmol/L towards lower values within the sequels of PPI re-challenge. 
2. The secondary goal was to identify a risk proﬁle in cases with PPIH. Therefore, the
traits age, gender, hypertension and the use of drugs were statistically tested with respect to 
nadir of magnesium under PPI regimen. 
Statistical analysis 
Changes in serum magnesium were assessed by an analysis performed for each of 
the two endpoints. All data were stored in an MS Excel spread sheet and subsequent statistical 
analysis and plotting was all done with GraphPad Prism (version 5; GraphPad Software Inc., La 
Jolla, CA, USA). (1st Endpoint): exponential regression analysis was performed on all suitable
withdrawal (observation 28 days) and re-challenge events (observation 21 days). We included 
curve ﬁtting and regression analysis and numbers with the graphs including means ± S.E.M. 
(standard error of the mean) and 95% conﬁdence intervals (95% CI) and sample size (n). (2nd
Endpoint): To detect possible correlations between the serum magnesium nadir under PPI 
regimen and the traits present in the cases a one-way-ANOVA analysis (95% conﬁdence 
intervals and Kruskal–Wallis with Gaussian approximation) was performed. The different 
group-combinations are described in the results section. Subsequent Bonferroni’s, Dunn’s or 
Tukey’s multiple comparison test was applied to detect differences between these groups (P 
< 0.05). Possible relationships between patient traits in respect to serum magnesium nadir 
were tested by Pearson’s correlation analysis, signiﬁcance level P = 0.05). Values are given as 
means ± S.E.M. and 95% conﬁdence intervals (95% CI) and sample size (n). 
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Results 
Literature research 
 Our comprehensive literature search identified in total 36 cases of PPIH since 2006, 
distributed over 18 articles (Figure 1) including one abstract (Weegh et al.), one review and 
one paper that was not accessible in full text to the authors (Francois et al.) (see also Table S1). 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic of applied literature search strategy on proton pump inhibitors induced 
hypomagnesemia. Depicted is the stepwise top to down procedure and assessment of case reports for 
primary and secondary endpoints. 
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Demography 
Our sample size consisted of 24 female (66.7%) and of 12 male individuals (33.3%). 
The age of the patients ranged from 30 to 83 years with a mean of 67.4 ± 1.9 years. In 75% of 
the cases omeprazole was observed to elicit hypomagnesemia, in 25% esomeprazole, in 14% 
pantoprazole, and in a few cases by lansoprazole and rabeprazole (total is more than 100% 
because in individual cases different PPIs were able to elicit PPIH, see Table S1). Most likely 
this reflects the market share of the different available PPIs. The time that elapsed between 
the start of PPI use and first clinical detection of PPIH ranged from 2 weeks up to 13 years, 
with a median duration 5.5 years (n = 30). 
Primary endpoint 
PPI withdrawal and re-challenge 
The screening of the case reports revealed nine papers containing data describing 
the short-term effects of withdrawal (Figure 2A: 17 episodes in nine individuals) and/or re-
challenge (Figure 2A: 19 episodes in seven individuals) suitable for intended analysis. Figure 
2B depicts the course of recovery of mean serum magnesium values after withdrawal of the 
PPI in nine different cases. The recovery halftime from the mean magnesium nadir of 0.41 
mmol/L (intercept with vertical axis) was 4.1 days (95% CI = 2.9–7.5 days). A serum magnesium 
of 0.6 mmol/L was reached after 4 days of withdrawal, the plateau of 0.81 mmol/L with 95% 
CI = 0.75–0.86 mmol/L was reached within 14 days after withdrawal. Figure 2B depicts the 
course of mean serum magnesium values after re-challenge with PPI in 7 different cases. 
Halftime from the mean magnesium peak of 0.72 mmol/L (intercept with vertical axis) was 5.6 
days (95% CI = 2.4-infinite days). After 4 days, 70% of the sampling points have fallen below 
the serum magnesium of 0.6 mmol/L cut-off. The calculated onset of plateau phase after re-
challenge 0.38 mmol/L (95% CI = 0.20–0.56 mmol/L) is comparable to that after withdrawal. 
The plateau phase starts early on day 4 (see dotted vertical line Figure 2A). The nadir of serum 
magnesium was 0.44 ± 0.05 mmol/L (95% CI = 0.35–0.54 mmol/L). 
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Figure 2: (A) Short-term effect of proton pump inhibitor (PPI) withdrawal on serum Mg2+ in PPI-induced 
hypomagnesemia. The horizontal axis reflects the number of days since PPI withdrawal. The vertical axis 
denotes the serum magnesium level in mmol/L (normal range 0.75–1.25 mmol/L, hypomagnesemia <0.70 
mmol/L). All single observations on any given time point, are plotted as open dots. The exponential 
regression line was derived from robust fitting of the means [r2 = 0.72, n = 76, Y0 = 0.41 mmol/L (95% CI 
= 0.37–0.46 mmol/L)]. (B) Short-term effect of pump inhibitors (PPI) re-challenge on serum magnesium in 
PPI-induced hypomagnesemia. The horizontal axis reflects the number of days since PPI restart. The 
vertical axis denotes serum magnesium levels in mmol/L (normal range 0.75–1.25 mmol/L, 
hypomagnesemia <0.70 mmol/L). All single observations are plotted as open dots. The exponential 
regression line was derived from fitting of the means [r2 = 0.40, n = 59, Y0 = 0.72 mmol/L (95% CI = 0.65–
0.79 mmol/L), plateau = 0.38 mmol/L (95% CI = 0.20–0.56 mmol/L)]. 
 
 
Nadir magnesium under PPI regime and peak outcomes after intervention 
 Outcomes were defined by normalization of serum magnesium by withdrawal of the 
PPI and/or other changes in treatment (see Discussion and supporting data available online, 
Table S1 and Figure S1). Mean serum magnesium nadir under PPI use was 0.22 ± 0.02 mmol/L 
(95% CI 0.18-0.26 mmol/L, n = 36). After intervention, magnesium levels returned to normal 
(mean = 0.80 ± 0.02 mmol/L, CI 0.77–0.84 mmol/L, n = 28). The remaining eight cases without 
final serum magnesium values reported were able to reach ‘normal magnesium’ levels. 
 
A B 
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Intervention 
Switching to H2RA occurred in 60% of the cases and in 25% of the cases PPI therapy 
could not been stopped due to inadequate acid suppression, whereas in six cases acid 
suppression therapy was discharged completely. To stabilize serum magnesium, 
supplementation was needed in 30% of the cases that switched to H2RA and in 80% cases that 
were maintained on PPIs. 
Secondary endpoint 
Patient at risk 
Secondary aim of this systematic review was to sketch a profile of the (classical) 
patient at risk. All PPIH cases suffered from considerable co-morbidity. Hypertension was most 
frequently described (55%) and there was widespread use of diuretics (36%). The cases were, 
therefore, grouped into ‘control’, ‘pure hypertensive’, ‘pure diuretic’ users and combined 
‘hypertensive & diuretic’ users, and by stepwise univariate analysis we tested whether or not 
nadirs of serum magnesium values between these groups (and all possible combinations 
thereof) were different. Furthermore, the same analysis assessed whether gender or age were 
predisposing risk factors. We could not detect significant differences (at P < 0.05) between the 
‘control’ group (‘no diuretic’ & ‘no hypertension’) and ‘pure hypertensive’ with respect to mean 
nadirs of serum magnesium concentration (control: mean = 0.26 ± 0.04 mmol/L, 95% CI 0.16–
0.36 mmol/L, n = 13 vs. pure hypertensive: mean = 0.17 ± 0.02 mmol/L, 95% CI 0.12–0.23 
mmol/L, n = 11) or patients on diuretics but not hypertensive (mean = 0.13 ± 0.03 mmol/L, 
9% CI 0.02–0.23 mmol/L, n = 4). Gender was no risk factor; women (mean = 0.24 ± 0.03 
mmol/L, 95% CI 0.19–0.30 mmol/L, n = 24); men (mean 0.17 ± 0.02 mmol/L, 95% CI 0.12–0.21 
mmol/L, n = 12). There was no correlation between age and nadir magnesium levels (Pearson's 
r = −0.1651, P = 0.34, n = 36). Stepwise Bonferroni's multiple comparison did not detect any 
differences between all groups (control, all combinations of hypertensive, diuretics users, non-
diuretics users, women and men) at significance level P < 0.05. 
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Other findings 
Electrolytes under PPI regime 
 Nine patients had severely low plasma calcium in phase with nadir hypomagnesemia, 
16 were moderately low, 8 showed a mild hypocalcemia. One was ‘normo-calcemic’ and 1 was 
hypercalcemic due to hypoparathyroidism (Table S1, marked *). Severe hypokalemia was 
present in only one case: <2.5 mmol/L), 20 cases were mildly to moderately hypokalemic 
(Table S1), in six cases the potassium levels were not affected. To investigate a possible 
correlation between the magnesium nadir and other electrolytes, the recorded calcium and 
potassium levels under PPI therapy were re-assessed. We were not able to detect a significant 
relationship between magnesium nadir and total plasma calcium (Pearson's r = 0.127, P = 
0.482) nor potassium (Pearson's r = −0.05, P = 0.86) (not shown). 
 According to the secondary aim we subsequently also tried to detect a possible effect 
of hypertension and/or diuretics on the correlation between serum magnesium nadir and 
calcium levels. Therefore, we analyzed if there are significant differences in magnesium and 
calcium between hypertensive, hypertensive diuretic users, only diuretic users and cases with 
neither hypertension nor diuretic use (control). No correlations within these groups between 
magnesium nadir and calcium values were detected and there were no significant differences 
between these groups (ANOVA & Tukey's multiple comparison test, significance level P < 0.05, 
data not shown). 
 
Symptoms at magnesium nadir 
 Most cases (n = 35) came to clinical attention when patients developed signs of 
symptomatic hypomagnesemia. The description of symptoms in episodes of severe PPIH 
included neuronal/mental, neuromuscular, cardiovascular and metabolic manifestations. Most 
commonly described were seizures (40%), followed by nausea or dizziness (36%), paresthesia 
(30%), vomiting and diarrhea (28%), muscle cramps and spasms (20%) and tetany (17%). 
Symptoms of weakness, fatigue or lethargy were present in 30% of the cases. Changes in 
cardiac rhythm were recorded in 30% of the cases. There was one case of epilepsy and one 
case of loss of consciousness reported. Some 20% of the cases presented other neurological 
impairments like numbness, perception problems, needles and pins feeling in feet and hands 
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or hallucinations (one case). In three of five cases there was an exacerbation of COPD (chronic 
obstructive pulmonary disease) linked to PPIH.33, 43, 44  
Renal magnesium excretion 
Renal magnesium excretion was documented in 33 cases and fell appropriately 
during the periods of PPIH (see Figure S2). Magnesium excretion over 24 h was measured in 
24 cases and varied between 6.42 mmol/24 h (possibly an outlier) and ‘immeasurable low’ 
indicating adequate renal magnesium retention. Mean magnesium excretion was 0.24 ± 0.05 
mmol/24 h (95% CI means: 0.14–0.34 mmol/24 h; three outliers were discarded: n = 21). 
Urinary magnesium correlated positively with low serum magnesium in state of magnesium 
depletion (Pearson's r = 0.60, 95% CI = 0.23-0.82, two-tailed P = 0.038, r2 = 0.36). 
Discussion 
We reviewed 36 cases with PPIH. This side effect is observed for all currently available 
PPIs and does not occur with other acid suppressants such as H2RA. All case reports document 
hypomagnesemia at different standard daily doses and PPIH reappears invariably when re-
challenged with the same or a different PPI. Collectively, this suggests that (i) the PPIH is a 
class effect and that (ii) once PPIH has established it persists with continuous use and always 
reappears after re-challenge. Time to onset of hypomagnesemia is highly variable and ranged 
from 14 days up to 13 years (mean 5.5 years). 
Most of the cases developed a magnesium-depleted state marked by severely low 
serum nadir (0.22 mmol/L) and strongly reduced renal magnesium retention. 
Hypomagnesemia recovered upon withdrawal (within 4 days to 0.6 mmol/L cut-off) whereas 
re-challenge with PPI's caused hypomagnesemia in a very short time frame (70% of 
magnesium determinations fell below 0.6 mmol/L, cut-off within 4 days). The onset of PPIH in 
re-challenge is brisk and gets apparent as soon as the body magnesium reserves are depleted. 
This shows that PPIH is not an intrinsic long-term effect of PPI's, but likely depends on the 
patients' magnesium status.36  
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 A pattern of risk factors uniting all cases of PPIH was not detected. Hypertension 
and/or the use of diuretics were common features in our population. However, multivariate 
analysis did not find a correlation between the nadir serum magnesium and these two 
parameters. In addition, PPIH arose independently from age and gender. An important finding 
from our study is that the side effect is not induced by other acid inhibiting drugs, because 
H2RA did not cause hypomagnesemia after substitution of PPI.28 There was no information on 
the long-term success rate of the alternative treatment and the need for persistent electrolyte 
supplementation. It has to be assumed that final outcomes are stable because there are no 
revisions known of any case reports concerning this matter. 
 That some cases could not withstand with H2RA and needed continuation of PPI 
could be explained by insufficient acid blockage or the appearance of other relevant side 
effects under H2RA antagonist therapy (e.g. rash). Success of acid reduction by H2RA might 
depend on individual fastening gastrin levels.45 High levels might overrule inhibition of the 
histamine-2-receptor of parietal cells and may result in insufficient acid reduction and rebound 
effects. 
 The majority of published PPIH cases reported herein lag the introduction of PPI 
almost by two decades. This may suggest that PPIH is less frequent than other forms of drug-
induced hypomagnesemia or suggests that it is missed because many cases are asymptomatic 
and routine measurement of serum magnesium does not take place. This is of concern 
because, in consequence of this, the prevalence of PPIH is unknown. Literature emphasizes 
that the importance of magnesium may be underestimated in daily routine at this moment.46, 
47 However, serum magnesium only gives limited information on total magnesium balance. On 
the basis of this study we think that there is no place for repeated magnesium measurements 
in the follow-up of all PPI users as the frequency of the side effect apparently is low. In the 
cases under investigation, magnesium levels prior to the appearance of symptoms of 
hypomagnesemia had not been recorded. Therefore, a suggestive benefit of magnesium 
measurements in all PPI users can only be proven by prospective long-term monitoring of 
magnesium in PPI users. This type of studies on PPIH have not been performed, but need to 
be done to investigate to which extend PPIH is also present in subclinical patients. 
 Drug-induced hypomagnesemia is not unique to PPI's. Other drug classes such as 
gentamycin calcineurin inhibitors (cyclosporine A and tacrolimus), platinum-based cytostatics 
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(cisplatin), Epidermal growth factor receptor (EGF-R) targeting drugs (erlotinib and cetuximab), 
and diuretics (furosemide, torasemide, bumetanide and thiazide-types) have all been 
associated with hypomagnesemia.48-53 For example, calcineurin inhibitors, cause 
hypomagnesemia in at least 10% of the users.54 Here, hypomagnesemia is inversely correlated 
to the dose of cyclosporine A and it is accompanied by low serum calcium. Relative to PPIH, 
hypomagnesemia induced by calcineurin inhibitors is less severe, and magnesium wasting is 
based on diminished renal TRPM6 (Transient Receptor Potential Melastatin 6) expression, 
which is the magnesium channel facilitating transepithelial magnesium transport under 
magnesium shortage and by this acts as a gatekeeper of total magnesium homeostasis.55 In 
contrast to PPI and cyclosporine A, the frequency of cisplatin-induced hypomagnesemia is 
exceptionally high. Ninety percent of cisplatin users develop hypomagnesemia (serum 
magnesium < 0.75 mmol/L) and 50% even severe hypomagnesemia (serum magnesium < 0.58 
mmol/L).56 The underlying mechanism is dose-dependent necrotic nephrotoxicity. In some 
cases, the outcome is persisting isolated renal magnesium wasting that suggests a selective 
and decisive renal tubular damage. So far, damage of renal epithelia by PPIs has only been 
observed by a limited number of case reports with idiosyncratic acute tubulo-interstitial 
nephritis (TIN).57 However, none of the cases reviewed here had TIN. The fact that PPIH is fully 
reversible suggests that irreversible structural changes do not underlie PPIH. Loop-type 
diuretics (furosemide) and thiazide-type diuretics have been shown to stimulate renal 
magnesium loss by lowering either passive magnesium reabsorption in thick ascending limb 
or indirectly act on magnesium homeostasis by blocking sodium reabsorption.40, 52 
Discontinuation of diuretics did not resolve PPIH, indicating their possible confounding role in 
PPIH to be low or absent.35  
We demonstrate that disruption of magnesium handling by PPIs is relatively fast and 
that the frequency of this side effect (at least severe PPIH) is low, as only documented by a 
few case reports.36 This supports the assumption of a genetic predisposition possibly 
underlying PPIH. However, a genetic screen of TRPM6 in one case failed to identify any risk 
alleles.40 TRPM6 is only one of the candidate genes critically involved in magnesium handling 
and, therefore, a broad genetic screen might uncover other regulatory genes.58 
In vitro experimental evidence suggests that cation transport through layers of 
colonic cells is strongly reduced at PPI treatment, which may be an observation in line with the 
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clinical picture of PPIH.59 In conclusion, tubular magnesium wasting has been shown for all 
other forms of drug-induced hypomagnesemia, but not for PPIH. Reported efficient tubular 
magnesium retention, therefore, sets PPIH apart from all other forms of drug-induced 
hypomagnesemia and suggests an intestinal involvement. 
 Most cases came to clinical attention because of differential combinations of 
neuronal, neuromuscular, cardiovascular and metabolic symptoms, typical for 
hypomagnesemia. Inadequate secretion of parathyroid hormone was the consequence of 
severe hypomagnesemia and resulted in secondary hypocalcemia in most cases, which was 
often the first biochemical indicator recognized by clinicians. A link to osteoporosis was 
suggestive, but only mentioned in one single case.26 This is remarkable, because it is 
assumable that in this highly comorbid selection of patients it might be more frequently 
present, independent from a possible involvement of PPI use. Either it was overlooked or 
beyond the scope of the clinical observation, which bears a concern for failure in treatment as 
magnesium supplementation then should be accompanied by long-term calcium 
bisphosphonate administration. 
 There was no typical patient profile that was unique for PPIH and the final attribution 
of the symptoms and electrolyte abnormalities to PPIH sometimes took years. In the absence 
of symptoms, identification of PPIH was purely dependent on chance.33, 39 
  
 Proper identification and treatment of PPIH therefore mainly rests on three pillars: 
First, serum magnesium monitoring on a regular basis. In event of existing hypomagnesemia 
discontinuation of PPIs should result in a rapid normalization, which may be supported by 
additional magnesium and calcium supplementation.60 This step is crucial to exclude other 
causes of the hypomagnesemia. Second, regular determination of serum magnesium (and 
concomitant other electrolytes) should be done to monitor the course of recovery. This should 
be accompanied by urinary magnesium measurements to assure renal magnesium retention. 
Third, patients with PPIH have the chance to escape hypomagnesemia by alternative acid 
suppressants. Therefore, switching to H2RA should be attempted.45 In cases of insufficient 
relief from acid related complains under H2RA, tapered or intermittent regimes including PPIs 
might be helpful. Also here, urinary magnesium monitoring is of benefit as it declines prior to 
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the serum magnesium as an early indicator.61 In most cases reviewed here, supplementation 
with electrolytes could be stopped after normal serum magnesium was obtained. 
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Abstract 
Background & aims: 
 Proton-pump inhibitors (PPI) are among the most widely prescribed drugs and used 
to treat gastric acid related disorders. Hypomagnesemia (PPIH) is a severe side effect of 
chronic PPI use. PPI withdrawal resolves hypomagnesemia but has tradeoffs in gastric acid 
protection. PPIH is caused by intestinal malabsorption of Mg2+. Given that fructo-
oligosaccharide-enriched inulin fiber increases colonic Ca2+ uptake by lowering the luminal 
pH, we hypothesized that inulin would be able to increase serum Mg2+ concentrations in PPIH. 
 
Methods: 
 To determine the prevalence of PPIH, 133 PPI users were screened for serum Mg2+ 
concentrations. A cohort of patients with PPIH was analyzed for host and genetic risk factors. 
We exposed 11 cases of PPIH and 10 controls to inulin in 2 subsequent treatment courses of 
14 days separated by a washout of 14 days. Serum Mg2+ levels served as the primary endpoint. 
 
Results: 
 We found that 13% of the PPI users had PPIH. Carriers of the TRPM6-related 
polymorphisms rs2274924 and rs3750425 had a 5.8 times higher risk for hypomagnesemia. 
Inulin enhanced serum Mg2+ levels by 0.1 mmol/L in PPIH patients and by 0.06 mmol/L in 
controls. Similar treatment effects were observed for serum Ca2+ (0.09 mmol/L) and serum K+ 
levels (0.07 mmol/L). Inulin produced mild transient intestinal discomfort, while symptoms 
related to hypomagnesemia clearly abated. 
 
Conclusions: 
 Dietary inulin increases serum Mg2+ concentrations under PPI maintenance in 
patients with PPIH. 
 
Keywords: Hypomagnesemia; Hypocalcemia; Proton-pump inhibitors; Inulin, Privet, Prebiotic, 
Short-chain fatty acid, SCFA, Prevalence, TRPM6 
 
NTC CLINICAL TRIAL NUMBER: NCT02518659, Trial registration date: June 2015  
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Introduction 
Proton-pump inhibitors (PPIs) are the mainstay for gastric acid related disorders and 
used by millions of patients for treatment and prevention of peptic ulcers, gastroesophageal 
reflux disease, and NSAID induced mucosal damage.1, 2 Over the last decade, evidence 
accumulated that PPIs may induce hypomagnesemia (PPIH).3, 4 Since 2006 many case reports 
and small case series highlighted the association which led the FDA to issue a warning on PPIH 
in 2011.5 PPIH may occur with all PPIs but is absent with other gastric suppressing agents such 
as histamine-2 receptor antagonists.6 PPIH may present with a wide spectrum of symptoms 
including, but not limited to, fatigue, vertigo, lightheadedness, numbness and gastrointestinal 
complaints.6, 7 PPIH occurs after prolonged PPI use, resolves in days after stopping, but 
rechallenge inevitably results in recurrence.6, 8 
PPIH is caused by intestinal malabsorption of Mg2+ as renal retention in PPIH cases 
is adequate.9, 10 PPIs may interfere with Mg2+ uptake in the large intestine which is facilitated 
by the epithelial Mg2+ channel transient receptor potential melastatin type 6 (TRPM6).11 
Stopping PPI results in resolution of PPIH, but many patients are dependent on PPIs since they 
do not respond sufficiently to histamine-2 receptor antagonists.12 An alternative therapeutic 
strategy would consist of measures to augment intestinal malabsorption of Mg2+. 
There are a number of outstanding questions. First, the exact prevalence of PPIH 
among users of PPI is unknown.6, 13 Second, it is unclear which genetic and clinical factors 
contribute to the risk for PPIH. Lastly, there is currently no satisfying treatment strategy to 
resolve PPIH while maintaining the desired acid suppressing effect of PPIs. 
This represents a real therapeutic dilemma, as oral Mg2+ supplementation is 
insufficient to treat PPIH. We hypothesized that prebiotics such as fructo-oligosaccharide-
enriched inulin fiber (inulin) may be beneficial in PPIH. Inulin is fermented by colonic 
microbiota, induces a decrease in the pH of the human culture medium which enhances 
intestinal uptake of Ca2+ and Mg2+  
Therefore, we designed a comprehensive study with 3 goals in mind: (i) to assess 
prevalence of and risk factors for PPIH in a random group of PPI users; (ii) to assess the 
contribution of TRPM6 variants to PPIH; (iii) to evaluate a PRebiotic InterVEntion Trial (PRIVET) 
to treat hypomagnesemia while continuing PPI use. PRIVET subjected PPIH patients with 
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profound hypomagnesemia to repeated 14-day trials with inulin supplementation to explore 
whether this strategy would increase plasma concentrations of Mg2+. 
 
Materials and Methods 
Prevalence cohort study 
 Between 2012 and 2013 PPI using outpatients were recruited from 3 hospitals in the 
Netherlands. Patients were categorized in 2 groups: hypomagnesemia (serum Mg2+ < 0.7 
mmol/L) and normomagnesemia (serum Mg2+ of ≥ 0.7 mmol /L. The diagnosis of PPIH was 
validated by at least one challenge – dechallenge cycle with PPIs. Selection criteria were PPIuse 
and > 18 yrs-of-age while patients were excluded with known alcohol abuse, uncontrolled 
diabetes mellitus, extremes of BMI (<16 or > 35) and short-bowel disease. 
 
Risk factor profiling 
 Differences in serum Mg2+ between subgroups were tested by student t-test, 
including Welch's correction where applicable. Pearson´s correlation test was applied for 
continuous values. Univariate categorical analysis χ2 was used to identify possible risk factors 
for hypomagnesemia and subsequently binary logistic regression analysis was used to study 
associations between the predefined risk factors and the hypomagnesemia. P < 0.05 was 
considered statistically significant. 
 
Genetic risk profiling 
 We collected DNA from PPIH patients who were part of our prevalence cohort study. 
In addition, DNA was obtained from 14 patients who were previously diagnosed with PPIH in 
our medical center. DNA was isolated using the HP-PCR Template Preparation Kit (Roche 
Applied Science, USA) and Polymerase chain reaction (PCR) was performed using primers that 
covered exon 26-27 of TRPM6 (Supplementary Table S1). Each targeted single-nucleotide 
polymorphism (SNP) site on PCR amplicons was sequenced with an ABI 3100 Genetic Analyzer 
(Applied Biosystems, USA). Hardy-Weinberg equilibrium for each SNP studied was confirmed. 
Frequencies were calculated for the 4 studied SNPs and compared between cases and controls 
using Pearson’s χ2 test (Fisher’s exact test was used where appropriate).14 Differences between 
continuous variables were tested using Student’s t-test and categorical variables by the χ2 test. 
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Haplotypes were generated with genotype data from the 4 SNPs. The relative risk attributed 
to haplotypes was calculated as odds ratios (OR) with a 95% confidence interval (CI) using the 
wildtype haplotype as a reference. Statistical significance was defined as P < 0.05.  
 
Prebiotic intervention trial (PRIVET) 
The prebiotic intervention trial (PRIVET) protocol was approved by the institutional 
review boards of the participating institutions CCMO (Centrale Commissie Mensgebonden 
Onderzoek Regio Nijmegen Arnhem) and the study was performed according to the 
Declaration of Helsinki. All patients provided written informed consent. The trial was registered 
at clinicaltrials.gov (NCT02518659). All study investigators had access to the study data, 
reviewed and approved the final manuscript. 
Cases of PPIH were collected between 2012 to 2014 from our prevalence cohort study 
or were included separately by one of our participating collaborators (Figure 2). Healthy 
controls were recruited from the community using advertisements in the local media. Patients 
with PPIH and healthy controls were subjected to a dietary intervention trial using fructo-
oligosaccharide inulin fibers. Inulin (Synergy 1, Orafti-Beneo, Belgium) was provided in 
containers prefilled with each 20 g. Participants were instructed to eat 20 gram inulin together 
with meals over the day. They were otherwise requested to maintain their dietary habits and 
continue the use of proton pump inhibitors. 
This study was designed as an open-label, unblinded trial. We elected not to 
randomize given: (i) the small number of cases; (ii) due to the lack of adequate blinding of 
inulin; (iii) in view of the hypomagnesemic state of the patients. Total study duration was 56 
days, divided into 4 periods of 14 days each. During days 0-14 and days 28-42 all participants 
were given 20 g/d inulin fiber product. Each of the supplemented periods was followed by a 
washout phase of 14 days. Primary endpoint was the determination of the serum Mg2+ 
concentration on day 0, 14, 28, 42 and 56. Secondary endpoints were serum Ca2+, K+ and Na+ 
concentrations in parallel determined at the indicated time points. We evaluated 24-h urinary 
Mg2+ and Ca2+ excretion in the PPIH group on days 27/28 and days 41/42 immediate prior to 
blood withdrawals. Type and severity of gastrointestinal symptoms, including abdominal pain, 
regurgitation, heartburn, and loss of appetite, were monitored by dedicated questioning. 
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Laboratory procedures  
Serum Mg2+, Ca2+, K+ and Na+ levels were determined using a Hitachi autoanalyzer 
(Hitachi, Japan) according to the manufacturer's protocol (Abbott Diagnostics, Belgium). 
Urinary Mg2+ concentrations were determined with a colorimetric xylidyl-II blue kit (Cobas 
Roche Diagnostics, UK) at 600 nm wavelength. Urinary Ca2+ concentrations were measured 
with a colorimetric chromogenic/buffer dual-component kit (Sigma Aldrich, UK) at 570 nm 
wavelength.  
 
Statistical analysis Privet trial  
The mixed models analysis was performed using the SAS 9.2 software package. For 
each of the electrolytes (Mg2+, Ca2+, K+ and Na+) a mixed model was used with fixed factors 
patient group (Control, PPIH), treatment (Inulin addition, no addition) and their interaction. To 
deal with the correlation of the repeated measured outcome within a patient a random 
intercept was included in the model. The model assumes that the effect of treatment can be 
different for the two patient groups (interaction) and that correlations between two 
measurements within a patient is the same for each combination. Using the mixed model the 
treatment effect, i.e. the difference of the mean outcome using inulin minus the mean outcome 
without inulin, for both patient groups was estimated and tested. Averaged values were 
reported as mean ± 95% confidence intervals. 
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Results 
Prevalence cohort study 
One hundred thirty-three random PPI users that visited the outpatient clinics and met 
the inclusion criteria were recruited for our hypomagnesemia screen (Figures 1 and 2). 
Prospective analysis of serum Mg2+ identified that 13% of individuals had hypomagnesemia 
(< 0.70 mmol/L) with a mean serum Mg2+ of 0.61 mmol/L (interquartile range [IQR], 0.55-0.68 
mmol/L), whereas the mean serum Mg2+ concentration of normomagnesemic PPI users was 
0.82 mmol/L (IQR, 0.77-0.86 mmol/L) (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Frequency distribution of serum Mg2+ (in mmol/L) in 133 Dutch PPI users. Bars represent 
fractions of the respective bins in % of total. Given values are centers of respective bins (width 0.1 mmol/L). 
Serum Mg2+ < 0.70 mmol/L is defined as hypomagnesemia. 
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Figure 2. Flow scheme of the Privet study. In chronological top-down order, the 3 parts of the study are 
section-wisely indicated by black bars. Depicted are the patient numbers and flows, as well as the 
performed analysis and respective main-endpoints (in italics). 
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Age, sex and BMI were equally distributed between the groups (Table 1). PPIH 
patients were longer users of PPI than PPI users with normomagnesemia with 7.7 years versus 
5.2 years respectively, and duration of PPI use significantly correlated to lower serum Mg2+ 
levels in the total study population (r=−0.16, P < 0.05). None of the hypomagnesemic patients 
had a significant renal impairment according to KDIGO guidelines (no CKD class).15  
 
Table 1 Basic Demographics 
 Low Mg2+ (n = 17) Normal Mg2+ (n = 116) Total (n = 133) 
Demographics    
 Age, y (range) 62 (46 - 83) 60 (20 - 90) 60 (20 - 90) 
 Sex, % m:f  41 : 59 44 : 56 44 : 56 
 Body mass index a 27.2  27.7  27.7  
Serum Mg2+    
 Mg2+, mmol/L b 0.61 ± 0.02 0.82 ± 0.01 0.79 ± 0.01 
PPI use    
 Duration, y b 7.7 ± 1.1* 5.2 ± 0.4 5.5 ± 0.4 
 Type c e:41 o:29 p:18 r:12 l:0 o:43 p:29 e:27 r:1 l:1 o:41 e:29 p:27 r:2 l:1 
 Dose, mg/d b 49.4 ± 5.2  46.3 ± 1.7  46.7 ± 1.7  
Comorbidities (%)    
 Hypertension 13 (77)* 51 (44) 64 (48) 
 Cardiovascular disease  11 (65)* 38 (33) 49 (37) 
 Hypercholesterolemia  8 (47) 38 (33) 46 (35) 
 Biliary tract 3 (18) 18 (16) 21 (16) 
 Diabetes mellitus d 5 (29) 15 (13) 20 (15) 
 COPD/Astma e 3 (18) 15 (13) 18 (14) 
 Liver disease 5 (29)* 10 (9) 15 (11) 
 Carcinoma 1 (6) 13 (12) 14 (11) 
 Hiatus hernia 2 (12) 10 (9) 12 (9) 
 IBD 2 (12) 8 (7) 10 (8) 
 Pancreatic diseases - 9 (8) 9 (7) 
 H. pylori infection - 7 (6) 7 (5) 
 Renal implication  - 2 (2) 2 (2) 
Indication (%)    
 Reflux / dyspepsia 9 (53) 55 (47) 64 (48) 
 
Protectant / 
comedication 5 (29) 28 (24) 33 (25) 
 Gastritis 1 (6) 23 (19) 24 (18) 
 Barrett / esophagitis 2 (12) 9 (8) 11 (8) 
 Unknown /others 1 (6) 3 (3) 4 (3) 
Medication (%)  
 NSAID f 5 (29) 39( 34) 33 (25) 
 Diuretics  5 (29) 22 (19) 27 (20) 
 Antidepressants 4 (24) 17 (15) 21 (16) 
 Benzodiazepines - 25 (22) 19 (14) 
     
aMean BMI. bMean ± SEM. cPercentage of PPI-type: esomeprazole (e), omeprazole (o), pantoprazole (p), 
rabeprazole (r), lansoprazole (l). dincluding insulin use. eChronic obstructive pulmonary disease (COPD). 
fNon-steroidal anti-inflammatory drug use. Significant differences between low Mg2+ and controls was 
determined by Fisher’s extract test on actual numbers with P < 0.05 indicated by * (refer to Table S7 for 
numbers and exact P - values). 
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Risk profiling 
We evaluated factors that might increase the risk for PPIH using χ2 testing and binary 
logistic regression analysis. Univariate χ2 analysis showed that hypertension, cardiovascular 
disease, and liver diseases were more frequently present in PPIH compared to PPI users with 
normal Mg2+ levels (P < 0.05, Table 1, Supplementary Tables S2-S4). Use of diuretics has been 
described to associate with PPIH before, in our population it failed association to 
hypomagnesemia (Supplementary Table S5).3 Diabetes mellitus, a possible confounding 
suspect being present in cases did not associate to the hypomagnesemia (Supplementary 
Table S6). Subsequently, stepwise multivariate regression analysis identified hypertension and 
liver disease as risk factors for PPIH after correction for covariates (P < 0.05, Supplementary 
Table S7).  
In order to identify whether TRMP6 SNPs constitute a genetic risk factor for PPIH, an 
extended cohort of 147 PPI users were sequenced for TRPM6 SNPs located to exon 26 
(p.Val1393Ile, [rs3750425]) and exon 27 (p.Lys1584Glu, [rs2274924]) (Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Linkage disequilibrium (LD) plot across hypomagnesemia SNPs on TRPM6. The box at the top 
shows the sequenced coding strand (in reverse direction). Indicated are the SNPs within the region. The 
hypomagnesemia SNPs rs2274924 and rs3750425 are located in the middle. Each diamond indicates the 
pair-wise magnitude of LD, with dark diamonds indicating strong LD (D’ > 0.8). LD = linkage disequilibrium 
is the non-random association of alleles at two or more loci. Linkage disequilibrium describes a situation 
in which some combinations of alleles or genetic markers occur more or less frequently in a population 
than would be expected from a random formation of haplotypes from alleles based on their frequencies..43 
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Rs3750425 and rs2274924 were significantly enriched among hypomagnesemic PPI 
users (Supplementary Table S8). Linkage analysis of genotyped SNPs showed close linkage 
(±78%) across the sequenced stretch (Figure 3). To determine effects of co-inheritance of both 
SNPs, odds ratios were calculated for PPIH (Table 2). PPI users who carry both rs3750425 and 
rs2274924 have a 5.83 fold increased risk to develop PPIH. 
 
Table 2. SNP-hypomagnesemia odds ratios 
 
 
 
 
 
 
 
The relative risk associated with haplotype SNP alleles was estimated as odds ratio (OR) with a 95% 
confidence interval (CI) using wildtype haplotype as reference. The four haplotype SNPs are arranged 
according to their chromosomic sequence position on the coding strand and represented as 4-way letter 
code with position 1=rs2274925, 2=rs2274924, 3=rs3750425 and 4=rs45616231 in agreement with Table 
S8. Highlighted is the haplotype combination of SNPs with highest OR for hypomagnesemia. 
 
PRIVET clinical trial: Primary outcome measure 
Thirty-nine suitable subjects (24 PPI-using cases of PPIH and 15 healthy non-PPI 
using controls) were enrolled in PRIVET (Figure 2, Supplementary Table S9). Before t=0, seven 
cases were excluded, due to illness, denial or lack of interest, one case could not be reached, 
two cases were excluded due to other reasons. From 29 allocated participants, three cases 
were excluded because serum Mg2+ concentrations were > 0.7 mmol/L at t=0. Five controls 
were excluded, due to intestinal complaints (n=1), violation of the study protocol (n=1), due 
to illness (n=1) and due to loss of interest (n=2), resulting in a final study population of 11 
cases and 10 healthy controls who completed the PRIVET study (Supplementary table S9). 
PPIH cases had mean baseline serum Mg2+ concentration of 0.60 mmol/L (95% CI, 0.54-
0.65 mmol/L), which increased to 0.68 mmol/L (95% CI, 0.63-0.73 mmol/L, P < 0.01) after the 
first period of dietary inulin supplementation (Figure 4B). In the same vein, the second inulin 
course enhanced serum Mg2+ concentrations from 0.61 (95% CI, 0.55-0.66 mmol/L) to 0.69 
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mmol/L (95% CI, 0.64-0.74 mmol/L, P < 0.01). In controls, serum Mg2+ levels increased 
significantly from 0.83 mmol/L (95% CI, 0.78-0.89 mmol/L) to 0.93 mmol/L (95% CI, 0.87-0.99 
mmol/L, P < 0.01) during the second course (Figure 4B). Dietary inulin increased serum Mg2+ 
concentrations with 0.1 mmol/L (P < 0.01) in PPIH patients and of 0.06 mmol/L (P < 0.01) in 
controls, when quantifying both treatment periods (Figure 4C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Effects of inulin on serum Mg2+ and 24-h urinary Mg2+ excretion. Depicted are the estimated 
least squares mean levels (ESLM) of serum Mg2+ (in mmol/L) during 56 days, bars indicate 95% CI limits 
(A+B). Inulin supplementation is indicated for days 0-14 and for days 28-42, in controls (A) and cases (B). 
The mean treatment effect of inulin per group is depicted in (C), bars indicate 95% CI limits. Values were 
derived from the mixed models analysis, significant treatment effects are highlighted by *, with P < 0.05. 
Panel D depicts the mean levels of urinary excretion of Mg2+ (in mmol/24h, ± 95% CI) before (day 27/28) 
and the end (day 41/42) of the 2nd 14 days period of inulin supplementation. Statistical analysis applied t-
test (one-sided) for Mg2+ and Ca2+, with Welch's correction for Mg2+. Significant differences are denoted 
by *, with P < 0.05. 
 
Urinary Mg2+ excretion analysis of PPIH cases prior to and after the second inulin course 
demonstrated that eight cases had baseline urinary Mg2+ concentrations below the threshold 
of quantification (< 0.2 mmol/L), while the remaining cases (n=3) had a mean of 0.29 
A B 
C D 
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mmol/24h (95% CI, 0.09-0.49) (Figure 4D). After 14 days of inulin urinary Mg2+ excretion 
increased to a mean of 2.20 mmol/24h (95% CI, 0.95-3.45, P < 0.01. 
PRIVET clinical trial: Secondary outcome measures 
To determine the specificity of the effect of dietary inulin supplementation on 
electrolyte homeostasis, we analyzed serum Ca2+, Na+ and K+ levels. During the 1st inulin 
course serum Ca2+ concentrations increased (2.27 to 2.41 mmol/L; P < 0.01, Figure 5A).  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 5. Effects of inulin on serum Ca2+ and 24-h urinary Ca2+ excretion. Depicted are the estimated least 
squares mean levels (ESLM) of serum Ca2+ (in mmol/L) during 56 days, bars indicate 95% CI limits (A+B). 
Inulin supplementation is indicated for days 0-14 and for days 28-42, in controls (A) and cases (B). The 
mean treatment effect of inulin per group is depicted in (C), bars indicate 95% CI limits. Values were 
derived from the mixed models analysis, significant treatment effects are highlighted by *, with P < 0.05. 
Panel D depicts the mean levels of urinary excretion of Ca2+ before (day 27/28) and the end (day 41/42) 
of the 2nd 14 days period of inulin supplementation (in mmol/24h, ± 95% CI). Statistical analysis applied 
t-test (one-sided) for Mg2+ and Ca2+, with Welch's correction for Mg2+. Significant differences are denoted 
by * with P < 0.05. 
 
A B 
C D 
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Moreover, the control group showed a significant increase of serum Ca2+ 
concentrations starting from 2.32 mmol/L to 2.42 mmol/L in the second treatment period (P 
< 0.05, Figure 5B). Serum Ca2+ levels showed a mean increase of 0.09 mmol/L over the two 
treatments periods (95% CI, 0.04-0.15 mmol/L, P < 0.01) in the PPIH group (Figure 5C). Urinary 
Ca2+ excretion increased significantly from 1.23 mmol/24h to 2.40 mmol/24h in PPIH cases (P 
< 0.01, Figure 5D). 
Serum K+ levels increased in PPIH cases during the 2nd inulin course (4.02 to 4.40 
mmol/L P < 0.01, Figure 6B). The overall mean treatment effects for inulin on serum K+ were 
only significant for PPIH with a net increase of 0.26 mmol/L (95% CI, 0.07-0.44 mmol/L, P < 
0.01) (Figure 6C). Inulin did not affect serum Na+ concentrations. (Figures 6D-F). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Effect of inulin treatment on serum K+ and Na+. Depicted are the estimated mean levels (in 
mmol/L, ± 95% CI) of serum electrolytes during the study period of 56 days. The top row shows the values 
for K+ in controls (A) and cases (B) and the respective mean treatment effect of Inulin in both groups (C). 
The bottom row shows the values for Na+ in controls (D) and cases (E) and the respective overall treatment 
effect of Inulin in both groups (F). Means were derived from the mixed models analysis, significant 
treatment effects are highlighted by *, with P < 0.05. 
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PRIVET clinical trial: Symptoms 
Seven patients with PPIH reported symptoms likely attributed to hypomagnesemia. 
Most frequently reported were paresthesia in hands and feet (event reports [ER], n=4), muscle 
cramps (ER, n=5), generalized weakness (ER, n=2), tetany of hands (ER, n=2), cardiac 
arrhythmia (ER, n=1) and nausea/vomiting (ER, n=1). Dietary inulin improved these symptoms. 
Three patients reported remission of paresthesia in hands and feet, 2 patients found that 
muscle cramps improved or disappeared. Tetany of hands disappeared in a single patient, 
while weakness improved in another. 
Introduction of inulin was associated with intestinal symptoms such as bloating, 
increased passage of flatus (ER, n=25) and boborygmi (ER, n=18), which regularly improved 
within the first week of therapy. Other commonly reported symptoms due to inulin 
supplementation were soft stools (controls (n=4) & cases (n=8)), fecal color changes (ER, 
n=11) and transient diarrhea (ER, n=8). One control patient prematurely stopped active 
treatment because of uncontrollable diarrhea after 5 days. 
 
 
Discussion 
The primary finding of our study is that a prebiotic strategy raises serum Mg2+ 
concentrations in patients with PPI induced hypomagnesemia. Fourteen days of inulin 
supplementation was sufficient to raise Mg2+ levels in patients on PPI maintenance. We saw 
that the beneficial effect was universal and reproducible, and occurred regardless of depth of 
hypomagnesemia. This resulted in a restoration of serum Mg2+ concentrations in the low 
normomagnesemic range in PPI users. As a consequence, PPIH-related symptoms improved. 
The cornerstone of PPIH treatment is PPI withdrawal, but histamine-2 receptor antagonists are 
often not effective in these patients.16 6 Alternative options to restore Mg2+ balance by Mg2+ 
supplementation is associated with side effects such as diarrhea and are insufficient to raise 
Mg2+ levels in PPI users.17 Inulin is a welcome alternative option to treat PPIH. Inulin increases 
serum Mg2+ in healthy controls, but the magnitude of increase in PPIH patients exceeded that 
of controls by a factor 2. These results are in line with previous observations documenting that 
inulin fibers enhance Mg2+ absorption in human volunteers.18, 19 
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The effect was not restricted to Mg2+ but other electrolytes such as serum Ca2+ and 
K+ also responded to inulin. Both minerals increased but stayed well within the normal range. 
Although serum Ca2+ and K+ levels were in the normal range in our study population, there 
have been reports of hypocalcemia and hypokalemia associated with PPIH.6 In line with earlier 
studies in healthy subjects using PPI, our PPIH patients had marginally decreased 24-h urinary 
Ca2+ excretion.20 Low serum Mg2+ suppresses parathyroid hormone secretion which curtails 
Ca2+ absorption and puts patients at risk for bone-fractures and/or osteoporosis.21 Inulin 
raised renal Ca2+ excretion in our population, but also stimulated intestinal Ca2+ absorption 
resulting in a net increase Ca2+ serum levels. As such this effect may contribute to the 
protection against osteoporosis in chronic PPI users.22 
The fact that inulin increases a number of minerals suggest a general mechanism of 
action. A common hypothesis is that as a result of ceco-colonic fermentation of inulin, short-
chain fatty acids are produced that lower intestinal pH, and absorption of minerals is improved 
under acidic conditions 23, 24 Indeed, the main intestinal Mg2+ channel, TRPM6, is more active 
in acidic pH range.25 Consumption of fermentable oligosaccharides increases true fractional 
Mg2+ and Ca2+ absorption in humans. 26, 27Not all minerals are sensitive to prebiotics and inulin 
fails to increase iron absorption in females with a low iron status despite a decrease fecal pH.28 
PPIH is not an infrequent finding. We found that 13% of regular PPI users have 
(a)symptomatic hypomagnesemia (<0.7 mmol/l). Although clinical awareness of PPIH has 
been improving over the last years, it remains underdiagnosed, and none of the patients in 
our cohort had properly been labeled with PPIH.4, 6, 17, 29 It is likely that prolonged PPI use 
depletes the body Mg2+ stores, and that latent PPIH is present in many PPI users.30, 31 
Hypomagnesemia-related symptoms can be transient, difficult to recognize and infrequently 
linked to PPI use. The prevalence in our cohort (13%) is considerably higher than found in 
other aged and regionally matched cohorts where the prevalence of 3.5% is seen 32-34, 35 
Presence of hypertension, but not use of diuretics, increased the risk for PPIH in our 
cohort. Mg2+ deficiency enhances reactivity of arteries to vasoconstrictors, promotes 
vasoconstriction, and increases peripheral resistance, leading to increased blood pressure. 
Mg2+ supplementation is associated with a significant decrease in blood pressure.36-38 39 It is 
tempting to speculate that restoration of serum Mg2+ levels improves blood pressure 
regulation in hypertensive PPI users. We found that 2 common TRPM6 SNPs (rs3750425, and 
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rs2274924) increase the risk for PPIH. Indeed these SNPs have previously been shown to 
associate with hypomagnesemia in diabetes mellitus.40, 41 TRPM6 genotyping may therefore 
provide a novel marker to identify patients at risk for PPIH. 
The strength of our study is its population-based nature. We estimated the 
prevalence of PPIH in an outpatient setting which supports the view that our results are 
generalizable to other populations. The adopted introduction-withdrawal design repeated 2 
cycles of inulin-based treatment. Such a design delivers evidence-based results and is easily 
translatable to a large variety of settings within daily clinical practice.42 The clinical effect on 
Mg2+ serum levels during both cycles was highly reproducible in and between patients 
suggesting a true treatment effect. The washout time was determined on basis of a previous 
systematic review that indicated that the PPIH is reversible in a few (<5) days.6 As such we 
avoided a carryover effect that was documented by the finding that serum Mg2+ returned to 
baseline levels within 14 days in all patients. A limitation of this study is the open-label, non-
randomized design. It would have been desirable to perform a randomized trial using matched 
controls. However, every patient was his/her own control and results were highly reproducible 
suggesting presence of adequate power. Another limitation was the relatively small number 
of participants (n=11). However, this is a sizable study population in view of the fact that a 
recent review identified a total 36 published cases of PPIH.6 
In conclusion, PPIH is common and inulin is a potent stimulator of intestinal mineral 
uptake. Inulin fibers were well tolerated by our study population and exerted a potent effect 
on intestinal Mg2+ absorption that was independent PPI use. This increased serum Mg2+ and 
abated PPIH related symptoms. These results provide a reasonable evidence base for a 
prebiotic treatment strategy in PPIH. 
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Supporting information 
 
Table S1. Primer sequences used in the TRPM6 screen 
SNP chr. pos. Forward primer Reverse Primer 
rs45616231 77378082 5'-GCAAATTCCCACTGGCTTAATG-3' 5'-CACAGTCAGGGCAGAGAGATC-3' 
rs3750425 77377410 5'-CAGAAACTGTCTTGCCTCTGT-3' 5'-GTCTTGTCCACTTACTGGAT-3' 
rs2274924 77376647 5'-TGTTCCCCACTTACTGTTGTCA-3' 5'-GGCCACTACCTTGACTGCTC-3' 
rs2274925 77376633 5'-TGTTCCCCACTTACTGTTGTCA-3' 5'-GGCCACTACCTTGACTGCTC-3' 
 
 
 
Table S2. Chi-square analysis: association of hypertension with PPIH 
  Value df Asymptotic Significance (2-sided) 
Pearson Chi-Square 6.275a 1 0.012 
Continuity Correctionb 5.041 1 0.025 
Likelihood Ratio 6.523 1 0.011 
Fisher's Exact Test       
Linear-by-Linear Association 6.228 1 0.013 
N of Valid Cases 133     
a0 cells (0%) have expected count less than 5. The minimum expected count is 8.18. 
 
 
 
Table S3. Chi-square analysis: association of cardiovascular disease with PPIH 
  Value df Asymptotic Significance (2-sided) 
Pearson Chi-Square 6.504a 1 0.011 
Continuity Correctionb 5.203 1 0.023 
Likelihood Ratio 6.253 1 0.012 
Fisher's Exact Test       
Linear-by-Linear Association 6.455 1 0.011 
N of Valid Cases 133     
a0 cells (0%) have expected count less than 5. The minimum expected count is 6.26. 
 
 
 
Table S4. Chi-square analysis: association of liver disease with PPIH 
  Value df Asymptotic Significance (2-sided) 
Pearson Chi-Square 6.405a 1 0.011 
Continuity Correctionb 4.496 1 0.034 
Likelihood Ratio 4.981 1 0.026 
Fisher's Exact Test       
Linear-by-Linear Association 6.357 1 0.012 
N of Valid Cases 133     
a1 cells (25%) have expected count less than 5. The minimum expected count is 1.92. 
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Table S5. Chi-square analysis: association of diabetes with PPIH 
  Value df Asymptotic Significance (2-sided) 
Pearson Chi-Square 3.152a 1 0.076 
Continuity Correctionb 1.994 1 0.158 
Likelihood Ratio 2.68 1 0.102 
Fisher's Exact Test         
Linear-by-Linear Association 3.128 1 0.077 
N of Valid Cases 133      
a1 cells (25%) have expected count less than 5. The minimum expected count is 
2.56. 
 
Table S6. Chi-square analysis: association of use of diuretics with PPIH 
  Value df Asymptotic Significance (2-sided) 
Pearson Chi-Square 1.000a 1 0.317 
Continuity Correctionb 0.459 1 0.498 
Likelihood Ratio 0.924 1 0.336 
Fisher's Exact Test       
Linear-by-Linear Association 0.993 1 0.319 
N of Valid Cases 133     
a1 cells (25%) have expected count less than 5. The minimum expected count is 
3.45. 
 
Table S7. Multivariate analysis: predictors of hypomagnesemia in PPI users 
univariate analysis, P < 0.1   after multivariate regression, P < 0.05 
Independent variable P-value P-value 
Hypertension 0.01 0.02 
Cardiovascular disease 0.01 - 
Diabetes mellitus 0.08 - 
Liver disease 0.01 0.04 
Univariates (with P < 0.1) were subjected to a multivariate regression analysis with 
significance level P < 0.05. 
 
Table S8. Haplotype SNP frequencies 
 SNP Type Assoc. alleles Cases Controls Chi square P value 
1 rs2274925 synonymous C:T(wt) 10:52 16:216 5.17 0.02 
2 rs2274924 missense G:A(wt) 19:43 31:201 10.35 <0.01 
3 rs3750425 missense A:G(wt) 11:51 8:224 16.54 <0.01 
4 rs45616231 non-coding T:C(wt) 10:52 20:212 3.01 0.08 
 
Selected SNPs in the TRPM6 gene were tested and match Hardy-Weinberg equilibrium (HWE), frequency 
numbers are provided for the distribution of the four studied SNPs. Highlighted are the 2 SNPs correlating 
to hypomagnesemia. Differences between continuous variables were tested using Student’s t-test and 
categorical variables by the x2 test. 
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Table S9. Basic demographics of inulin trial participants 
    Cases (PPIH) Controls 
    n=11 n=10 
Demographics 
  Age, y (range) 64 (46-76) 49 (23-75) 
  Sex, m:f (n) 6:5 5:5 
  Dose PPI, mg/d 62.2 ±6.3 - 
Baseline serum electrolytes (mmol/L) 
  Mg2+ 0.60 ± 0.03 0.85 ± 0.03 (*) 
  Ca2+ 2.27 ± 0.04 2.36 ±0.05 
  Na+ 141 ± 1 141 ± 1 
  K+ 3.99 ± 0.14 4.30 ± 0.13 
Values are represented as mean ± SEM 
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Background 
 In 2006 the first cases of proton pump inhibitor (PPI)-induced hypomagnesemia 
(PPIH) were reported in the New England Journal of Medicine.2 Since, the striking causality 
between PPI use and (severe) hypomagnesemia has become the most recognized side effect 
of PPIs. Clinical signs of symptomatic PPIH are indistinguishable from other forms of 
hypomagnesemia and include variable combinations of neurologic, neuro-muscular and 
cardiovascular symptoms of various severity.3 Frequently, PPIH is accompanied by secondary 
electrolyte imbalances such as hypocalcemia and hypokalemia. The central paradigm of PPIH 
is that it is induced by impaired intestinal Mg2+ absorption, while renal Mg2+ retention seems 
to be unaffected.4 The exact pathophysiological molecular mechanism is unclear and it 
possibly involves genetic risk factors.5,6 The growing number of cases worldwide suggests that 
its clinical impact is higher than anticipated previously.5-11 This chapter summarizes and 
discusses the work presented in this thesis that aimed to elucidate the molecular mechanisms 
of PPIH and to provide clinical solutions to prevent or treat the hypomagnesemia. 
 
 
Why do PPIs cause hypomagnesemia: The hypothesis 
 Chapter 2 examines the effect of omeprazole on the Mg2+ homeostasis of wildtype 
CB57BL/6J mice, in order to identify the molecular mechanism that underlies PPIH. 
Omeprazole treatment of these mice did not induce hypomagnesemia. However, it enhanced 
mRNA levels of the Trpm6 gene in the distal colon, whereas mRNA levels of other 
magnesiotropic genes did not change. Concomitantly, mRNA levels of the colonic H+,K+-
ATPase increased as well.  
The colonic H+,K+-ATPase is a homolog of the gastric H+,K+-ATPase which is the native 
substrate for PPIs and which is upregulated by omeprazole.12 We therefore speculate that 
omeprazole inhibits non-gastric (colonic) H+,K+-ATPase-mediated proton secretion, leading 
to local pH increases at the luminal side (Figure 1). 
Given that TRPM6 channel function is potentiated by luminal protonation, a local drop in 
available protons causes reduced Mg2+ transport via TRPM6, which was compensated by 
increased mRNA levels.13 
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Figure 1. Hypothesized molecular model of PPIH. Panel A depicts normal proton secretion in the colon 
by the non-gastric H+,K+-ATPase located on the luminal membrane of colonoctyes. In 
microenviromental proximity, available protons bind to luminal residues of TRPM6, facilitating apical 
Mg2+ influx. By unknown extrusion mechanisms, Mg2+ is released to the basolateral side and enters the 
bloodstream. Panel B sketches PPIs blocking the non-gastric H+,K+ -ATPase and reducing luminal 
extrusion of protons. Consequently, protonation of TRPM6 is reduced, eventually leading to 
compromised Mg2+ influx that may reduce blood Mg2+ levels. 
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 The postulated molecular target of all PPIs is the gastric H+,K+-ATPase with its specific 
luminal cysteine residues.14 Comprehensive labeling studies in mice revealed that radioactive 
omeprazole reaches all organs prior to accumulation at the canaliculi of the parietal cell in the 
stomach.15 However, the absolute specificity suggested by these studies is challenged by other 
in vivo experiments that show PPIs to accumulate in colonic tissue, although not as intense as 
in parietal cells. For instance, Nakamura et al. have demonstrated that the tritium labeled 
lansoprazole localizes to the apical membrane of the colonic epithelial cell, likely at the same 
location where the TRPM6 channel is expressed.16, 17 These studies provide additional support 
for our hypothesis that predicts off-target effects of PPIs.  
 
 
(Re-)defining the patient at risk 
Common comorbidities in case reports 
The literature contains several case reports and small case series on hypomagnesemia 
as an important side effect of PPIs. A systematic analysis of the data that allowed a better point 
estimate of the risk was lacking. To this end, Chapter 4 reviews 36 of the case reports on PPIH. 
The most important observation is that withdrawal of the PPI invariably resolves PPIH 
regardless of patient comorbidity and nadir of serum Mg2+. Most prevalent coexisting 
conditions were hypertension and/or use of diuretics but our analysis does not reveal any 
significant correlation to documented nadir of serum Mg2+ and PPIH seems to be independent 
of age and gender. 
In most patients, it is not known when PPIH started to develop as it may stay silent for many 
years of chronic PPI use. This view is supported by data from cohort studies and the models 
that suggest that small unrecognizable reductions in Mg2+ homeostasis may precede PPIH.18-
20 The exact consecutive factors or confounders, that may underlie the etiology of PPIH, are 
unknown. Danziger et al. detected small reductions of serum Mg2+ secondary to PPI use only 
by adjusting for several confounders while serum Mg2+ changes were absent in H2RA users.19 
A study performed by Biyik et al. did not detect hypomagnesemia in a group of outpatient PPI 
users (and respective controls) that did not have any of the possible risk factors that affect 
serum Mg2+.21 Another cross sectional study in a regionally matching population by 
Siadmoradi et al. identified a hypomagnesemia prevalence of 4.6%. Thus, it is plausible that 
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PPIH does not depend on a single trait. Consequently, it seems of multifactorial origin and 
several confounders prime only a few patients to develop symptomatic PPIH. 
 
The prevalence of hypomagnesemia in PPI users 
The cohort studies performed on the topic of PPIH are exclusively of retrospective 
nature and prospective data are missing.19, 22 Chapter 5, therefore prospectively and randomly 
sampled serum Mg2+ in 133 PPI using outpatients. We show that 13% of participants had 
hypomagnesemia with a serum Mg2+ concentration below 0.7 mmol/L. Although, 
hypomagnesemia is not uncommon in ICU patients (20 to 65%), it is less prevalent in similar 
cohorts (4.7%) or in the cross-sectional Dutch population (2% in the population with age >55 
years).23-26 Our observation that 13% of PPIH users have hypomagnesemia is in line with the 
findings of others.27 Two data mining approaches on the FDA database recently indicated that 
1% of all PPI adverse event reports related to hypomagnesemia and counted 1500 co-
occurrences of (es-) omeprazole and hypomagnesemia.28, 29 Moreover, the FDA issued an 
official warning on this side effect in 2011 due to continuously appearing reports.19, 30, 31 The 
publication of several Dutch cases and small case series indicates that PPIH is not a topic of 
regional (US) interest but that the risk is present regardless of population or ethnicity.6, 7, 9, 10 
 
Finding common risk factors in PPI users 
 Hypomagnesemia in patients can have multiple causes. Except for gastrointestinal 
losses, also low dietary intake, renal losses (drug-induced or alcohol abuse) and more seldom, 
genetic disposition can elicit hypomagnesemia (reviewed in 32). Moreover, hypomagnesemia 
in humans is associated with many diseases such as disorders of neurological origin (e.g. 
Parkinsons disease), diabetes mellitus, cardiovascular diseases including hypertension, 
preeclampsia and chronic kidney disease.33-36 
We screened a cohort of PPI users, aiming to identify the patient at risk for PPIH. The 
degree of comorbidity in our hypomagnesemic patients is variable. In Chapter 5, we searched 
for a possible underlying comorbidity pattern. We analyzed demographic traits such as age, 
gender, duration of PPI use and focused on the most common comorbidities hypertension, 
cardiovascular disease, diabetes mellitus and the use of diuretics. The statistical model shows 
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that hypomagnesemia strongly associates to the duration of PPI use and to hypertension, but 
not to diuretics use or other factors (Chapter 5).  
The observation that duration of PPI use may play a role in generating 
hypomagnesemia has been indicated before by several case reports.37, 38 However, in Chapter 
4 we did not detect such association with respect to the nadir of serum Mg2+ value. This can 
be explained by the dynamics of serum Mg2+ in Mg2+ depleted patients proven by drug (de-
)challenge. In Chapter 4, we exclusively analyzed symptomatic cases with strongly manifested 
hypomagnesemia and with considerable spread on individual nadir serum Mg2+ values. There 
is no systematic data available that describes the stability (or degree) of hypomagnesemic 
serum values under Mg2+ depletion. Moreover, the onset of PPIH upon PPI use is unclear, as 
the serum Mg2+ value not always reflects body Mg2+ deficiency and Mg2+ depletion is variable 
in onset and symptoms.39, 40 Thus, we do not know, when PPIH started before it 
symptomatically emerges patients. 
 The finding that hypertension significantly associates with hypomagnesemia has not 
been reported before in cohorts of PPI users or in case series. Experimental and 
epidemiological studies show a role of Mg2+ deficiency in the pathophysiology leading to 
hypertension (reviewed in 41). In vitro data suggests that hypomagnesemia increases vascular 
tonus which in vivo causes narrowing of capillary and venial vasculature leading to arterial 
hypertension.42, 43 This mechanism may be dependent on the degree of dietary Mg2+ 
deficiency.43 For instance, a long term clinical study demonstrates that the shortage of dietary 
Mg2+ intake that is reflected by low fractional urinary excretion may determine the risk for 
hypertension.44 In addition to that, PPI use is associated with lower urinary Mg2+ excretion.45 
In Chapter 5, we also observed low Mg2+ excretion in the patients with PPIH. This observation 
fits to the low serum Mg2+ levels and is the typical sign for intestinal Mg2+ malabsorption due 
to PPIs.37  
 Studies in other populations have identified the use of diuretics as a risk factor for 
reduced serum Mg2+ in PPI users, whereas diabetes was not a risk factor.46, 47 In a 7-year 
retrospective study in intensive care unit patients, only PPI users with concomitant use of 
diuretics had reduced serum Mg2+ levels. The risk increase for hypomagnesemia was small 
(odds ratio 1.54) and the decrease of mean serum Mg2+ by ~0.01 mmol/L (0.028 mg/dL) is 
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undetectable in the single patient or small cohorts.19 We failed to identify diuretics as a risk 
factor in Chapters 4 and 5 but we may have been limited by the low number of observations. 
Finding a genetic marker for PPIH 
The central aspect in our hypothesis on the molecular etiology of PPIH is reduced 
activity of the TRPM6 Mg2+ channel in the intestine, which is a key regulator of human Mg2+ 
homeostasis (Chapter 2, Figure 3).8, 48-51 Clinical studies assume that the TRPM6 could play a 
role in PPIH as its currents are strongly enhanced by protonation of luminal residues. 6, 13 At 
the same time, a possible genetic disposition is vaguely proposed.6 To our knowledge, a gene-
directed analysis was done only in one case without a clear result.5, 6 
 It has been shown that dietary Mg2+ intake inversely associates to diabetes in a dose-
dependent manner. 52 The TRPM6 single nucleotide polymorphisms V1393I [rs3750425] and 
K1584E [rs2274924] lead to enhanced risks for diabetes in individuals that have Mg2+ intakes 
lower than 250mg per day, which is lower than recommended daily allowances (Chapter 1).53 
We speculate that these SNPs may cause reduced Mg2+ (re-) uptake and contribute also to 
PPIH.  
 In Chapter 5, we performed a haplotype frequency analysis of TRPM6 SNPs using 
our cohort that was enriched with several cases from Chapter 4. The frequency analysis shows 
that carriers of the TRPM6 SNPs V1393I and K1584E have a 5.8 times increased risk for 
hypomagnesemia. These desensitize the TRPM6 channel to insulin-dependent activation and 
may predispose to develop diabetes.54 Nair et al. reason that a failure of channel 
phosphorylation and reduced translocation of functional TRPM6 channels to cell membrane 
probably contributes to onset of diabetes.54 They show that single SNP carrying TRPM6 
channels are already functionally affected.54 Reduced insulin sensitivity may lead to 
hypomagnesemia, resulting in impaired ß-cell function and insulin secretion and/or reduced 
insulin receptor sensitivity.55,54 
 The exact pathophysiological effect of TRPM6 SNPs towards PPIH remains to be 
elucidated. In the kidney, the insulin receptor is expressed in the distal convoluted tubule of 
the kidney, together with TRPM6.54 Carriers of the polymorphisms may therefore have a 
reduced efficacy of renal Mg2+ retention, which may confer to hypomagnesemia. An 
impairment of renal Mg2+ retention has never been observed in cases of PPIH, albeit it cannot 
be excluded that small (subclinical) losses were not properly detected by routine laboratory 
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measures.4, 20 Moreover, most of the patients have low fractional Mg2+ excretion under 
severely low serum Mg2+ levels, which does not exclude that under normal Mg2+ load (after 
elimination of the Mg2+ depletion) renal retention may still be reduced in SNP carriers.4, 56  
 The role of the insulin receptor concerning intestinal nutrient transport is not well 
characterized.57-59 It is possible that SNP carriers may have a curtailed colonic TRPM6 surface 
expression. It is tempting to speculate that SNPs may affect the channel function and further 
contributes to the risk of PPIH. The value of this genetic marker needs further clarification, but 
we postulate that the detected SNPs could be used in prediction profiling for the patient at 
risk. 
 
Implications for Ca2+ homeostasis 
Severe PPIH frequently occurs in combination with secondary hypocalcemia (Chapter 
4). The first cases, described by Epstein et al. had absence of increased serum parathyroid 
hormone (PTH), physiologically needed to counteract the hypocalcaemia. Before the initial 
report of PPIH, insufficient PTH levels have also been observed by Subbiah et al. in 2002, 
however they did not investigate serum Mg2+.60 During our studies only two cases came to 
clinical attention with insufficiently (normal) low PTH levels being prediagnosed before the 
hypomagnesemia, however with low to normal serum Ca2+ (Chapter 5, unpublished data). The 
hormonal regulation mechanisms of Ca2+ are well known.61 Mg2+ and Ca2+ homeostasis are 
partly interlinked and in physiological context antagonize each other.62-65 Secondary 
hypocalcemia is a consequence of hypomagnesemic suppression of PTH release from the 
parathyroid gland and skeletal resistance to PTH.66-69 
 Impaired Ca2+ homeostasis is the second most debated topic in long term PPI use. 
Epidemiological studies suggest that chronic PPI use increases the risk for bone fractures, but 
the data on the role of duration of use or the dose of PPIs being used is inconsistent.70-72 For 
instance, studies trying to elucidate a possible anti-osteoporotic effect of PPIs show no 
inhibition of osteoclastic activity in patients.73 After switching from H2RA to PPIs, urinary 
calcium excretion decreases while serum Ca2+ levels remain stable, indicating that intestinal 
Ca2+ absorption is reduced by PPIs. This negative effect is confirmed by a recent study showing 
that PPI users not only have reduced renal excretion of Mg2+ but also 17% lower Ca2+ 
excretion, without PTH levels being measured.45 However, a prospective study by Sharara et 
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al. shows that 12 weeks of PPI use did not affect Ca2+ metabolism or PTH levels in young 
healthy males.74  
In Chapter 3 we confirm, that omeprazole affects Ca2+ homeostasis. Omeprazole 
significantly reduces serum Ca2+ (and Mg2+) in mice, while the principal Ca2+ channel Trpv6 in 
the intestine together with the intestinal Ca2+ binding protein S100g is increased. The mRNA 
levels of the respective renal counterparts Trpv5 and Calb1 however do not change. Patients 
with osteoporosis did not have a higher risk for hypomagnesemia (Chapter 5, unpublished 
data). In Chapter 5, urinary Ca2+ excretion is low under PPIH. These findings are consistent 
with the observation that both renal Mg2+ and Ca2+ excretion may be reduced in PPI users.45 
The clinical findings and the marked influence of omeprazole on Ca2+ homeostasis highlight 
the need for revisiting the impact of PPI use on Ca2+.  
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Towards the integral treatment strategy for PPIH 
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 Figure 2. Clinical treatment chart for PPIH. Depicted is the top-down process of successful treatment 
of PPIH in patients. In first instance, classical supplementation therapy applies to gain control of 
hypomagnesemia in PPI users. Correct reassessment of hypomagnesemia is needed. TRPM6 SNPs can be 
screened to identify the additional risk. When hypomagnesemia in PPI users is resistant to classical 
treatments, secure diagnosis is needed to validate the existence of PPIH. If PPIH is diagnosed, several 
treatment options may apply depending on indication for PPI use. Golden standard is PPI withdrawal, but 
most difficult. We propose inulin in given dose and adjuvant oral Mg2+ supplementation together with life 
style advices for all types of patients. PPIH requires constant monitoring of serum Mg2+ and symptoms, 
whereas changes in drug regimen need to be assessed on gastrointestinal complaints. 
 
 
 
Classical approaches 
Since the discovery of PPIH, a few treatment strategies have been applied to 
overcome the hypomagnesemia by means of (i) parenteral or (ii) oral Mg2+ supplementation, 
(iii) acute withdrawal or (iv) tapering of PPI combined with eventual (v) substitution by H2RA 
(Figure 2). 10, 30, 75  
 Parenteral supplementation of Mg2+ is indicated at acute symptomatic 
hypomagnesemia. The treatment of PPIH is similar to that of other forms of hypomagnesemia. 
Parental Mg2+ supplementation provides immediate but only temporary relief from 
hypomagnesemia and recurrence is the rule.76  
 Oral supplementation maintains adequate serum Mg2+ levels in otherwise 
asymptomatic hypomagnesemic patients.77, 78 PPIH is characterized by blockage of intestinal 
Mg2+ absorption. Therefore, oral or dietary Mg2+ is prone to fall short in increasing serum 
Mg2+. This is supported by findings from others, it is confirmed in Chapter 4 and observed in 
the patients of Chapter 5.30 Moreover, orally administered Mg2+ salts bear the risk to induce 
osmotic secretory diarrhea, a state that most likely worsens hypomagnesemia and thus is 
contraindicated for patients with poor tolerance.79 
 Acute PPI withdrawal is the only means to uncover PPIH as it will result in prompt 
restoration of serum Mg2+ without any further supplementation. However, in clinical practice 
it is difficult to enforce, as it can lead to long lasting rebound hypersecretion of gastric acid 
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(Chapter 4), which is difficult for patients with good indication for PPI use (e.g. erosive 
esophagitis or peptic ulcers).80 
 Gastric acid rebound can be limited by combining gradual PPI tapering and 
additional use of H2RA (at high dosage) together with oral antacids.75 Whenever Mg2+ 
containing antacids are used, the doses of other oral Mg2+ supplementation should be 
adapted accordingly in order to prevent diarrhea. The success of this strategy strongly 
depends on baseline acid production, compliance and indication for PPI use, and might be 
tried as documented in Chapter 4.81, 82  
 
Prebiotic inulin treatment to counteract PPIH in mice 
 The central hypothesis of Chapter 2 is based on the reduction of H+,K+-ATPase-
mediated proton secretion due to PPIs. Thus, increasing the local pH in the colon that hampers 
TRPM6-mediated Mg2+ influx. Chapter 3 investigates whether prebiotic acidification of the 
large intestine by dietary inulin fibers can counteract PPI-induced pH increases, in order to 
reestablish a milieu that facilitates TRPM6-mediated Mg2+ absorption. 
 Inulin fibers naturally occur in chicories, onion, garlic and other crops. They are used 
as functional food ingredient by the food industry and are accepted as safe (GRAS) by the 
FDA, making them easily applicable for human use.83, 84 There is a large body of evidence 
showing that inulin fibers stimulate intestinal Mg2+ and Ca2+ absorption in humans and 
animals.85, 86 The mechanism of action depends on bacterial fermentation of inulin in the large 
intestine that leads to the production of short-chain fatty acids (SCFA).87-91 
 We evaluated the effect of inulin administration on serum and urine electrolytes in 
C57BL/6 mice. Omeprazole-treated mice showed clear reductions in serum Ca2+ and Mg2+ 
concentrations mimicking clinical PPIH (Chapter 3).18, 19 Inulin corrected serum Ca2+ but not 
Mg2+ levels. In line with these findings, omeprazole-induced elevations of mRNA levels of the 
Ca2+ channel Trpv6 in the intestine, together with the intestinal Ca2+ binding protein S100g 
were normalized. Inulin- enhanced renal Mg2+ excretion under omeprazole indicated that 
intestinal absorption of Mg2+ was stimulated. The latter was reflected by inulin-induced 
reductions of TRPM6 levels in cecum and kidney, irrespective of the omeprazole treatment. 
Moreover, our observations are in line with the only other available study on inulin mediated 
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effects on TRPM6 expression.92 Impaired intestinal Ca2+ uptake by PPI is currently neglected. 
Our results highlight the need for reissuing this topic. 
 TRPV6 expression patterns along the gastrointestinal tract slightly differ between 
mice and humans.1 In humans, the epithelial Ca2+ channel is predominantly expressed 
proximally, whereas in mice additionally high expression is found distally.1 Consequently, 
described effects of inulin on Ca2+ in humans are challenged by the question on location and 
identity of Ca2+ transport in the large intestine, the place where inulin fermentation happens 
(further discussed later). Experimental evidence shows that the distal intestine is not 
completely devoid of paracellular Mg2+ and Ca2+ transport.1 This suggests that tight junctional 
fluxes could be affected by PPIs in an pH dependent fashion.93, 94 Functional data shows that 
permeability for Mg2+ and Ca2+ as well as their selectivity is altered by protonation of TRPM6.13 
Likely, the molecular mechanism by which PPIs reduce intestinal Ca2+ absorption may be based 
on the same aspects as PPIH, but it needs further elucidation. 
 In Chapter 3, we suggest that deficient renal Mg2+ retention can explain the failure 
of inulin to correct serum Mg2+. Still, effects of SCFAs in the kidney are poorly understood. It 
has been shown that SCFAs protect against acute kidney injury by reducing inflammation.95 
Animal experiments show that SCFAs cause vasodilatation, increasing renin secretion and 
tubular flow by increased glomerular filtration rate.96 This may explain why inulin fails to 
stabilize PPIH in Chapter 3. Nevertheless, Chapter 2 and 3 are both in concordance by 
showing that omeprazole triggers the expression of intestinal H+,K+-ATPase, which in Chapter 
3 was normalized by inulin. This evidence supports the view that inulin counteracts the central 
acid-related hypothesis of PPIH. 
 
Prebiotic inulin treatment to counteract PPIH in patients 
In Chapter 5, dietary inulin increased serum Mg2+ levels by 0.1 mmol/L and serum 
Ca2+ by 0.09 mmol/L in 11 patients with PPIH. Thereby, PPIH ameliorated closely towards 
normal serum Mg2+ values. Intestinal toleration of the doses of inulin was good and side 
effects were mild (mainly stool softening). Close monitoring showed that hypomagnesemia 
related symptoms quickly disappeared, which may have promoted patient compliance to 
steady inulin intake. 
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 The stimulation of intestinal Mg2+ and Ca2+ uptake by inulin are in line with the 
literature.85, 86, 97 The major difference between the outcome of the animal inulin study 
(Chapter 3) and the treatment effects being observed in the clinical trial in (Chapter 5), 
concerns increase of serum Mg2+. The absence in mice is explained by insufficient renal 
retention, being reflected by reduced renal TRPM6 expression. The positive treatment effect 
for Mg2+ was also observed in healthy controls of the clinical trial. Moreover, the treatment 
effects in cases is independent of the presence of investigated TRPM6 SNPs in Chapter 5, 
suggesting that stimulation of intestinal Mg2+ absorption was of such magnitude that it may 
have compensated other possible obstructions. 
 Likely, TRPM6 expression patterns in humans and mice are comparable in the kidney 
and the intestine.98, 99 Mice are good models for intestine-related pathophysiology and the 
obtained results have, therefore, a adequate translational power.99 However, the intestine of 
multivorous humans shows a few anatomical differences compared to that of herbivorous 
mice.100 Although the gut to body surface ratio is similar in mice and humans, the ratios of 
different segments is not.101 For instance, the central segment in which bacterial fermentation 
takes place, the cecum has rudimentary function in humans where fermentation localizes 
solely to the colon.102, 103 Thus the differential reaction to 14 days of inulin treatment under 
omeprazole may be based on differences in physiology. Importantly, clinical cases all used 
PPIs for years, which may explain the stronger stimulation of Mg2+ absorption and Mg2+ 
retention resulting in serum Mg2+ increases, contrasting the outcome in relatively short term 
treated mice. Thus, logically patients with depleted Mg2+ status may benefit stronger from 
inulin stimulated Mg2+ absorption. Bodily needs prime them for quick replenishment, which is 
in line with the rapid normalization of serum Mg2+ we observe in Chapters 4 and 5. 
 
 
Clinical implications and recommendations 
 The sequence of experiments and clinical investigations support the hypothesis that 
impaired acid secretion in the large intestine is the causative factor in the mechanism for PPIH. 
Firstly, it is observed that PPIs increase mRNA levels of the non-gastric H+,K+-ATPase, reflecting 
increased mRNA levels of the gastric H+,K+-ATPase upon inhibition by PPIs. Secondly, PPI 
treatment elevates the mRNA levels of TRPM6 in mice, probably triggered by low Mg2+ influx, 
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by reduced Mg2+ availability and/or by reduced cellular Mg2+ levels. Thirdly, carriers of SNPs 
that ablate insulin-stimulated TRPM6 function have an increased risk for hypomagnesemia. 
Thus additionally to the pH-related diminution of Mg2+ transport this indicates that TRPM6 is 
a crucial player in PPIH. Fourthly, stimulating SCFA production by bacterial fermentation of 
inulin fibers leads to acidification of the distal intestine, which stimulates Mg2+ and Ca2+ uptake 
under PPI treatment. Based on these findings and the comprehensive experience gained in 
the clinical context, we therefore present the following recommendations to master the critical 
health care related aspects of PPIH. 
 
Recommendation 1: Identification of hypomagnesemia 
 Effective identification of PPIH needs to be improved. Hypomagnesemia remains 
undetected in most cases because of: (i) neglect of (weak) diffuse symptoms, (ii) false 
ascription of symptoms to other possible causes, (iii) missing hypomagnesemia simply to the 
lack of measurements. The central key to treatment success of PPIH is the clinician’s awareness. 
 
Recommendation 2: Monitoring patients at risk 
 Based on our experience and supported by the epidemiological data, PPIH is not 
infrequent and it has direct impact because our patients had significant symptoms. 
Additionally, multiple comorbidities may imply extra health risks due to the hypomagnesemia. 
Especially patients with PPIH related comorbidities such as hypertension should undergo a 
periodic electrolyte profiling including serum Mg2+ determination. Interpretation of serum 
electrolytes in the light of PPIH requires great care. Clinicians need to be aware of the fact that 
PPIH develops in a slow and subclinical fashion. This means it insidiously and silently affects 
human electrolyte homeostasis over years, giving the body time to adapt over years before it 
gets symptomatic. Moreover, currently used serum Mg2+ determinations lack signaling 
sensitivity for Mg2+. Normal plasma Mg2+ values do not necessarily indicate adequate 
intracellular Mg2+ levels and therefore should be supported by quantification of 24-hrs renal 
Mg2+ excretion. It is plausible that renal excretion may be a more sensitive indicator for 
subclinical reductions of electrolyte homeostasis under PPI use. 
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Recommendation 3: classical and inulin-based treatments for PPIH 
Hypomagnesemia resolves upon discontinuation of PPIs. However, uncontrollable 
gastric acid rebound may appear after PPI withdrawal. Therefore, we evaluated tapering of PPI 
use, which is effective only in few cases.104 Classical Mg2+ supplementation should follow 
clinical routine protocols. Parenteral Mg2+ administration should be performed under close 
monitoring of serum electrolytes and secondary Ca2+ or K+ shortages should be supplemented 
when needed. Oral Mg2+ supplementation may be successful in cases with residual intestinal 
Mg2+ uptake. Inulin can be used additionally to stimulate intestinal Mg2+ absorption. To allow 
a generalized advice on inulin treatment, randomized long term studies need to validate the 
inulin effect that we observed in our trial patients (treatment procedures summarized in Figure 
2). Inulin intake may exert additional beneficial health effects in patients.100, 101 It enhances 
glycemic control in patients with diabetes probably reducing insulin resistance.105, 106 However, 
this protocol should be used not as only means to treat patients with PPIH, as the ultimate 
elimination of hypomagnesemia still relies on discontinuation of the PPI (Figure 2). 
 
 
Reflection 
A main strength of this thesis is that it systematically examines PPIH on multiple 
levels. The experiments and clinical investigations resulted in new insights into (i) the 
molecular mechanism, (ii) the general risk factors for PPIH, (iii) a genetic trait and finally (iv) a 
novel clinical treatment approach using inulin fibers. 
Concerning animal experiments 
 Mice are valid models to study the mechanisms of electrolyte transport, the 
mechanisms of disease, genetics and the pharmacology/toxicology of PPIs.107-109 Limited by 
the lack of any known models for PPIH, we subjected wildtype C57BL/6 mice to oral 
omeprazole treatment. However, complex patterns of comorbities, the influence of chronic PPI 
use, differential gene expression being present in patients, remain difficult to be recapitulated 
in a mouse model. This hampers translational research in this area. Despite these limitations, 
this thesis hypothesized a pH dependent molecular model affecting the crucial regulator of 
Mg2+ homeostasis TRPM6 (chapter 2). Subsequently, we challenged this molecular hypothesis 
on physiological basis by inulin treatment (chapter 3). As a side effect, lately underrated 
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impact of PPIs on Ca2+ was evaluated and Ca2+ treatment effects by inulin stimulated to 
implement it into a clinical trial. 
Concerning clinical aspects 
In our prevalence study, the number of participants is limited. This is mostly due to 
poor recognition of patients as Mg2+ determination is not part of the routine laboratory 
testing. For instance, the prevalence study increased clinical awareness and led to the 
identification of several additional PPIH cases that came to our clinical attention. An important 
limitation of this thesis is that the genetic analysis was restricted to TRPM6. To circumvent this 
limitation, we subjected DNA from 10 proven PPIH cases to a SNP array and checked for 
genetic variants that predict hypomagnesemia. However, no additional genetic risks were 
found. Subsequently, we focused on TRPM6 and performed a complete analysis of the coding 
region by high resolution melting curve analysis and found that that exon 26 and 27 
contributed mostly to the PPIH risk. It remains to be seen whether these TRPM6 variants may 
serve as markers for PPIH.  
 We used an observational trial design to estimate the treatment effects of inulin fibers 
in patients with PPIH. This study was limited by (i) the low number of participants, (ii) the lack 
of a matched control group and (iii) the lack of blinding and randomization. However, the 
novelty and positive treatment outcomes will stimulate further investigation on prebiotic 
intervention methods in PPIH. Even after its initial recognition almost 1 decade ago, there are 
many open ends concerning the molecular etiology of PPIH and concerning clinical aspects of 
PPIH. 
 
 
Outcomes to central research questions and goals 
 What is the molecular mechanism of PPIH and which are the molecular players being 
involved? The molecular mechanism of PPIH is of intestinal origin and likely depends on a 
reduction of large intestine proton availability due to aspecific PPI-induced non-gastric 
H+,K+-ATPase inhibition. This impairs TRPM6-mediated Mg2+ absorption and additionally 
it may affect TRPV6-mediated Ca2+ absorption as well. 
 What is the current prevalence of PPIH? The prevalence of PPIH is 13% which is high, 
based on seldom case reports. By this, PPIH has clinical impact. 
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 Which are the determinants in patients predisposing for PPIH? Patients with multiple 
comorbidities are at risk for PPIH. These especially include long term PPI users with 
hypertension that possibly carry additional confounders. 
 Does a TRPM6-mediated disposition contribute to PPIH? The risk for hypomagnesemia 
is 6 times higher in carriers of common TRPM6 SNPs. It is tempting to use these genetic 
predictors for the patient at risk. 
 Are there alternative strategies that can be utilized to improve the treatment for 
PPIH? PPIH treatment depends on success of identification, thus serum Mg2+ screens are 
inevitable despite their restricted sensitivity. Measuring renal Mg2+ excretion may be a 
sensitive means to detect PPIH. Treatment should follow normal supplementation 
procedures accompanied by tapering of PPI, switching to H2RA, and/or addition of dietary 
inulin fibers, which may enable continuation of PPI therapy. 
 
 
Future research agenda 
 Evaluate and implement new advanced methods to detect intracellular Mg2+ in order 
to prevent PPIH before Mg2+ depletion. 
 Evaluate PPI-induced segmental reductions of intestinal Mg2+ and Ca2+ absorption in 
mice following the approach of Lameris et al.1 
 Include electrolyte compromised mouse models or mouse models with common 
PPIH key comorbidities. 
 Identify protein-drug interactions of PPIs (in situ detection). 
 Evaluate protein expression changes in the intestine upon PPI treatment. 
 Perform  
 Evaluate long term efficacy of inulin treatments on electrolyte and health status of 
cases of PPIH. 
 Include randomized cohort studies in order to further develop tailored patient 
treatment protocols. 
 Evaluate if subtypes of short bowel patients may benefit from inulin treatment. 
 Evaluate if other types of Mg2+ compromised patients benefit from inulin treatment 
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 Identify a possible influence of PPIs on the composition of the gut microbiome in 
cases of PPIH. 
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mijn attentie. Het magnesiumtekort dat door “onschuldige” maagbeschermers ontstaat is 
interessant onderwerp! Op korte termijn kwam ik terug en we voerden onder de leiding van 
René een officieel sollicitatiegesprek. Ik wist wel dat er “proefkonijnen“ in 
basiswetenschappelijk onderzoek nodig waren maar ik werd sneller proefkonijn dan verwacht, 
een persoonlijkheidstest stond voor de deur. Ik zag mij ambities al onder bedwang komen. 
Een telefoontje met jullie gaf dan toch snel grote opluchting en ik mocht dan ook spoedig in 
februari 2011 beginnen aan de grote, nieuwe uitdaging promotie. 
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me. Je hebt een uitgesproken betrouwbare wetenschappelijke gut-feeling. Je stond altijd klaar 
om op de werkbesprekingen beslissingen te stimuleren en het onderzoek richting te geven. 
Dank voor de constructieve en goede evaluatiegesprekken. Beste Joost D., zonder jouw 
expertise, je netwerk en de inzet van de afdeling MDL hadden we een essentieel doel van het 
onderzoek niet kunnen bereiken: Vooruitgang in de patiëntenzorg omtrend de bijwerking van 
maagzuurremmers. Je goede relatie tot gastro-enterologen van de omliggende ziekenhuizen 
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bij het schrijven van de klinische stukken. Leider können wir jetzt keine Besprechungen mehr 
in deutscher Sprache führen. Falls Du dennoch einmal eine gute Übersetzung einer 
Zusammenfassung brauchst, dann melde dich einfach bei mir. 
Beste Jeroen, je was veel meer dan een goede collega en goede copromotor over de jaren. Er 
was altijd ruimte voor persoonlijke gesprekken en je voortreffelijke mensenkennis en empathie 
zijn (naast jouw wetenschappelijke expertise natuurlijk) erg kenmerkend voor je. Je merkt 
meteen als er iets aan de hand is. Ik bewonder de kunst waarmee je met mensen kunt omgaan. 
Ik heb altijd genoten van de avonden die we samen met collega´s konden besteden. Ik heb 
ook genoten van je kunstzinnigheid. Hartelijk dank voor je grote bijdrage aan dit proefschrift. 
Je manier van focusseren is ongelofelijk goed! 
Anke. Wat heb jij een grote berg aan werk verzet tijdens je promotie. Het project waarop ik 
werd aangenomen was ook jouw kindje. Je verzorgde een erg goede start voor me op het lab. 
Ondanks dat onze samenwerking niet altijd even soepel verliep hebben we toch samen een 
erg goed stuk kunnen publiceren. Dank voor de fantastische hulp met alles en in het bijzonder 
met de dierexperimenten. Op het juiste moment bracht jij de inuline onder de aandacht. 
Hiermee kon het project essentiële vooruitgang boeken. Jammer dat er niet nog meer mensen 
met jouw breede en speciale expertise in de ion transport groep zaten. Het was een erg 
vreemd gevoel voor ons allemaal toen je voor je huidige baan vertrok en op eens niet meer 
bij ons op de afdeling zat. Dank ook voor alle persoonlijke gesprekken en je eerlijkheid. 
Hiervan heb ik veel kunnen leren. 
Sjoerd, toen ik 2008 stage binnen jouw TRPV5 project liep werd me al snel duidelijk dat 
wetenschap ook wel frustrerend kan zijn. We probeerden een eiwit-eiwit interactie aan te 
tonen en dat wilde maar niet lukken. Je hebt me de basis van het wetenschappelijke werken 
op een onderzoekslab geleerd. Sinds die tijd beheers ik de Western blot techniek en het 
kloneren blind. Gelukkig had ik deze techniek niet steeds nodig voor mijn eigen project. Ik heb 
zelden iemand ontmoet die zo veel enthousiasme laat zien en betrokken is bij iedereens 
onderzoek. Je wetenschappelijke expertise is cruciaal voor de afdeling. Je bent altijd vriendelijk 
en open voor een gesprek. Dank voor al je hulp 
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Ellen, (alias EviL). Dank voor het organiseren van de pub quizzen en de verjaardag versiering. 
Je bent erg sociaal en een sympathieke collega (toch wees je me destijds erg streng erop dat 
ik de vluchtdeur van het weeg hok niet als afkorting moest gebruiken, maar dat deed je dan 
wel met veel charme). Ik wens je van harte een beetje geluk met het verdere verloop van je 
promotie. Dit komt zeker goed, want je bent een harde werkster en hebt de juiste discipline. 
Volhouden zo! 
Oh ja, en Liz (Elisabeth). Hoofdvertegenwoordigster van de “roze piep-unit“ (samen met EViL). 
Toen ik naar de andere (koude) kant van het lab moest verhuizen baalde ik daar van. Er was 
altijd iets te lachen aan jullie kant. De soms inspannende dagen werden daardoor een flink 
stuk aangenamer. Ik vrees dat je dit boekje pas na je promotie in handen houd. Veel sterkte 
met je verdediging en je toekomstige carrière. Mogelijk begin je straks toch nog aan je eigen 
bedrijf (Oil of O´Liz)? 
Lolo (Lauriane). Sorry, even though I tried to improve my French by talking to you in your 
native language, I do not dare to use it here. I didn’t make it for the duck dinner (je regrette 
beaucoup). Thanks for all the discussions and conversations. I like your directness and honesty, 
which is spiced with a good portion of French attitude and a lot of humor. I wish you all the 
best with finalizing your doctorate and I hope that next Christmas you will win the “ugliest 
Christmas present contest”. Maybe you should try it with toe shoes? 
Maxime. Without you in our unit (lab-)life would have been not the same. I have great respect 
for your writing and your scientific skills, and besides of that (and very important) you are a 
very calm and nice person. Your presence worked quite moderating on me, thanks a lot. Even 
though, you only by chance survived the poo-meltdown, you are otherwise always under 
control of the situation. We should have done more cycle tours. It was great fun! I hope that 
we will meet again sometime (you know that I am planning to travel to Canada). 
Paco, (alias Francesco, Parkito, Arjono, Pacote, master of fishomics). The “German Spanish” on 
the lab. I never met a guy with this discipline and endurance. But more importantly, you are a 
very social and empathic person fitting into and completing the magnesium unit. Thanks for 
all the conversations and discussions! 
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Andreas, dank voor het lenen van je lab gereedschappen en de Duitstalige conversaties die 
soms wel eens voor wat irritatie en verwondering zorgden in de magnesium unit. Ondanks dat 
het vaak hektisch was in de unit bleef jij altijd kalm en straalde rust uit. De publicaties komen 
zeker nog en ik wens je heel veel succes met je promotie. 
Steef, je wist wel waaran je begon. Dus ook voor jou geld: Doorgaan, de resultaten komen er 
vast wel. Dank voor de goede werk muziek in de late avond uren en weekenden. 
Lieve Irene, jouw bijdrage in onze afdeling is van onschatbare waarde en dit betreft zeker niet 
alleen het bestellen van laboratorium materiaal. Met alle problemen kon ik je benaderen en 
samen zochten we naar “oplossingen“. Hartelijk dank voor je inzet en al je toespraak. 
Beste AnneMiete, je was de centrale pijler op het lab. We missen je allemaal. Je 
dierexperimentele expertise en je ervaring op alle vlakken maar ook je persoonlijkheid. Het 
was altijd leuk van je reizen te horen. Ik hoop het gaat goed met je en je kunt veel van je vrije 
tijd genieten! 
Het lab MDL werd tussendoor mijn tweede Heimat. Dank Hennie, Jody en René voor jullie 
inzet! Het moleculaire klinische werk was zonder jullie expertise (en jullie Taq) niet mogelijk 
geweest. Ook voor de rebuttal van het dierexperimentele werk in context van de inuline 
behandeling hadden jullie een passend antwoord paraat. René, zelden heb ik een dermate 
slimme analist mogen leren kennen met zo een brede expertise. Jammer dat je niet erin kon 
slagen om mijn niveau van rikken te verbeteren. 
Beste Femke L., dank voor al je hulp. Je had altijd een goede raad. Dank voor het helpen met 
de TRPM6 constructen. Dank ook aan Caro en Marla! 
Dank ook aan het secretariaat, met name Sjoeli, Esther en natuurlijk Femke K. 
Tijdens de promotie heb ik met groot plezier een aantal dappere studenten mogen 
begeleiden. Rob, Lucas en Daan. Hartelijk dank voor jullie bijdrage. Ik hoop dat jullie ook op 
de promotie aanwezig kunnen zijn. 
De dierstudies in dit boekje waren zonder de medewerkers van het centraal 
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